Antigen-binding domain with reduced clipping rate
Patent Information
- Application Number
- JP2023526549
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-08
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-11-08
AI Technical Summary
Clipping or fragmentation of biomolecules, such as antibodies, during liquid storage is a significant issue that compromises stability and uniformity, particularly in regulated environments like the pharmaceutical industry, necessitating improved methods to reduce clipping rates.
A polypeptide or polypeptide construct with a VH and VL variable region connected by a peptide linker comprising S(G4X)n or (G4X)n, where X is Q, T, N, C, G, A, V, I, or M, and n is an integer from 1 to 20, replaces the conventional S(G4S)n linker to reduce clipping rates.
The modified linker significantly decreases the clipping rate of antigen-binding domains, ensuring stability and feasibility of liquid formulations without the need for lyophilization, thereby enhancing safety and reducing production costs.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to a polypeptide or polypeptide construct comprising a first target antigen-binding domain, wherein the first target antigen-binding domain comprises VH and VL variable regions linked by a peptide linker, the peptide linker comprising or consisting of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20. The present invention also relates to a method for improving the stability of the polypeptide or polypeptide construct. Furthermore, the present invention relates to a polynucleotide encoding the polypeptide or polypeptide construct of the present invention, a vector comprising the polynucleotide, and host cells transformed with or into which the polynucleotide or vector has been transferred. Furthermore, the present invention also provides a process for producing the polypeptide or polypeptide construct, and a pharmaceutical composition comprising the polypeptide or polypeptide construct of the present invention. In addition, the present invention relates to the medical use of the polypeptide or polypeptide construct, and a kit comprising the polypeptide or polypeptide construct. [Background technology]
[0002] Clipping, also known as fragmentation, of assembled and purified biomolecules, such as antibodies and T-cell engager antibodies, during liquid storage, is a widely observed drawback. Depending on the rate of clipping, liquid formulations may not be feasible without compromising the stability, and therefore composition, of the biomolecule. Such compromises are not always an option, especially in highly regulated environments such as the pharmaceutical industry, where providing functional, homogeneous, and stable medicines is paramount. Because biomolecules have diverse shapes, structures, and functions, there is an ongoing need to improve the stability of biomolecules by reducing the clipping rate, i.e., the rate at which clipping occurs. One method to reduce clipping is, for example, lyophilization of biomolecules. However, the need for lyophilized formulations can significantly impact the flexibility of commercial production and therefore the cost of manufactured goods (COGM) may be higher. Another option is to manipulate the biomolecules themselves to make them less prone to clipping, and in particular to enable liquid formulations of biomolecules. Biomolecules versus lyophilized liquid formulations, for example, eliminate the need for error-prone reconstitution processes of lyophilized materials, thereby improving safety and ease of handling. Clipping also occurs, particularly in polypeptides or polypeptide constructs containing antibody-derived binding domains, such as scFv. In such cases, there is an ongoing need to reduce the clipping rate of the corresponding biomolecules. [Overview of the Initiative] [Means for solving the problem]
[0003] The present invention relates to a polypeptide or polypeptide construct comprising a first target antigen-binding domain, wherein the first target antigen-binding domain comprises VH and VL variable regions linked by a peptide linker, the peptide linker comprising or consisting of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20. The peptide linker substitutes the S(G4S)n or (G4S)n linker linking the VH and VL variable regions, wherein the substitution is preferably a conservative substitution, i.e., the linker length remains the same in the substituted binding domain and the unmodified binding domain. The substitution reduces the clipping rate of the antigen-binding domain with the substitution compared to the antigen-binding domain without the substitution, i.e., with the S(G4S)n or (G4S)n linker. The clipping rate can be analyzed by methods well known in the art, preferably by reductive capillary electrophoresis (rCE-SDS) as described later in this specification and in the Examples section, to evaluate the amount of low molecular weight (LMW) species as a readout for the clipping rate. [Modes for carrying out the invention]
[0004] The term “polypeptide construct” (or “compound” as it is used herein) refers to an antigen-binding (or epitope-binding) molecule that includes the paratope-containing binding domain itself. In the context of the present invention, a polypeptide construct is understood as an organic polymer comprising at least one contiguous, unbranched amino acid chain that is not naturally occurring but has been manipulated. An example of a polypeptide construct that is a single polypeptide, and also a preferred embodiment, is a BITE® molecule comprising a core structure containing at least one functional target antigen-binding domain on a single polypeptide chain together with at least one fully functional CD3-binding domain, where these domains are directly linked by a flexible peptide ("linker") without any insertion domains, unlike, for example, Xmab, which contains a target-binding factor and a CD3-binding factor on different polypeptide chains. In connection with the present invention, similar polypeptide constructs comprising multiple amino acid chains are also envisioned. The term “polypeptide” is preferably used in relation to the single-chain form of the compounds of the present invention, but “polypeptide construct” may be more appropriately used to describe polypeptides comprising multiple polypeptide chains, for example, two, three, or four polypeptide chains. However, unless expressly specified herein, both terms are used interchangeably herein. Preferably, the polypeptide or polypeptide construct of the present invention is a single-chain polypeptide or polypeptide construct. In addition, the term “polypeptide construct” is also suitable to describe the compounds of the present invention that include one or more non-amino acid components. The amino acid chain of a polypeptide typically contains at least 50 amino acids, and preferably at least 100, 200, 300, 400, or 500 amino acids. Also in connection with the present invention, it is also conceivable that the amino acid chain of a polymer is linked to an entity that is not composed of amino acids.
[0005] This polypeptide comprises structural and / or functional features based on the structure and / or function of an antibody, e.g., a full-length immunoglobulin molecule. Therefore, the polypeptide construct binds specifically, preferably selectively, or immunospecifically to its target or antigen, more precisely to the epitope of the target or target antigen, and includes naturally occurring heavy chain variable regions (VH) and light chain variable regions (VL) in the antibody, or domains derived from the antibody. Thus, the construct may be considered to include paratope-like structures and epitope-binding structures as found in natural antibodies or fragments thereof. The polypeptide constructs according to the present invention include the minimum structural requirements of an antibody that enables immunospecific target binding, i.e., a paratope that, unless otherwise specified, immunospecifically or immunoselectively recognizes an epitope on a target antigen. This minimum requirement can be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VL region, also referred to as CDR-L1, CDR-L2, and CDR-L3), and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VH region, also referred to as CDR-H1, CDR-H2, and CDR-H3), preferably all six CDRs. Thus, a polypeptide construct may be characterized by the presence of three, or preferably six, CDRs in the binding domain, and those skilled in the art will know where (in what order) these CDRs are located within the paratope binding structure. In accordance with the present invention, and with respect to the first target antigen-binding domain of the polypeptide or polypeptide construct, the paratope binding structure is thus identified as a target antigen-binding domain characterized by the presence of VH and VL regions containing CDRs. Therefore, the polypeptide / polypeptide construct according to the present invention comprises at least one paratope-binding structure which is a binding domain that selectively, immunospecifically, and / or immunoselectively binds to a target antigen comprising a VH variable region and a VL variable region (having a CDR). Thus, the polypeptide / polypeptide construct according to the present invention comprises a paratope that selectively, immunospecifically, and / or immunoselectively binds to a target antigen.As used herein, the term “antigen-binding structure” refers to any polypeptide / polypeptide construct comprising an antigen-binding structure or any molecule having binding activity to a particular target antigen. The antigen-binding structure or antigen-binding molecule is not limited to those of biological origin and may, for example, be a polypeptide resulting from an artificially designed sequence. The antigen-binding structure or antigen-binding molecule may also be any of the following: a natural polypeptide, a synthetic polypeptide, a recombinant polypeptide, etc. Since the antigen-binding structures according to the present invention specifically bind to a portion of an antigen, the antigen (epitope)-binding structure may also be broadly defined herein as a “paratope structure.” Accordingly, the polypeptide / polypeptide construct according to the present invention may also be defined as a domain comprising a paratope that preferably binds immunospecifically or immunoselectively to a target antigen / target epitope, and in certain embodiments comprising at least one further paratope, preferably binds immunospecifically or immunoselectively to further, different or the same target antigen / target epitope. Therefore, whenever this specification refers to a construct or molecular domain of the present invention, the construct comprises at least one paratope structure (or paratope) that binds a target antigen, preferably such as CD3 and / or a tumor antigen, as specified herein, particularly by any one of the appended claims. In certain embodiments, the construct comprises at least one further paratope / binding domain that binds a further target antigen as defined herein.
[0006] As used in accordance with the present invention, the term "antibody" includes full-length antibodies, including camel antibodies and other immunoglobulins produced by biotechnological or protein engineering methods or processes. These full-length antibodies may be, for example, monoclonal antibodies, recombinant antibodies, chimeric antibodies, deimmunized antibodies, humanized antibodies and human antibodies, as well as antibodies derived from other species such as mice, hamsters, rabbits, rats, goats or non-human primates.
[0007] The polypeptide / polypeptide construct of the present invention comprises a linker that ligates the VH and VL regions of a binding domain, preferably resulting in an scFv, and / or, in other embodiments, comprises at least one further binding domain containing a paratope, and such polypeptide / polypeptide construct does not exist in nature and its function differs significantly from that of naturally occurring products. For this reason, the polypeptide or polypeptide construct of the present invention is an artificial "complex" molecule comprising an scFv and / or, in some embodiments, a separate paratope / binding domain having different specificities and / or selectivity.
[0008] As described above, the polypeptides / polypeptide constructs of the present invention may include multiple polypeptide chains, i.e., polypeptides comprising two or more polypeptide chains, in particular polypeptides that form a three-dimensional protein-like structure enabling immunospecific binding to at least one target antigen, are also subject to the present invention. Therefore, the definition of the term “polypeptide construct” includes molecules consisting of only one polypeptide chain and molecules consisting of two, three, four or more polypeptide chains that may be identical (homodimers, homotrimers, or homooligomers) or different (heterodimers, heterotrimers, or heterooligomers). Examples of the antibodies identified above and their fragments, variants, derivatives, and constructs derived therefrom are described, in particular, in Harlow and Lane, Antibodies: A laboratory manual, CSHL Press (1988); Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010; and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009.
[0009] The "polypeptide / polypeptide constructs" of the present invention may also include fragments of full-length antibodies such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd(VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "rIgG" (a "half-antibody" consisting of a heavy chain and a light chain), but since they are defined as including VH and VL regions linked by a peptide linker, obviously not all of the above fragments are applicable to the first target binding domain, although they are applicable to embodiments relating to at least one further binding domain. The polypeptide / polypeptide constructs according to the present invention may also include modified fragments of antibodies, also called antibody variants or antibody derivatives. For example, scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabody, single-chain diabody, tandem diabody (Tandab), tandemzi-scFv, tandemtri-scFv, structures such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2, multibodies such as triabody or tetrabody, and VHH, Examples of “minibodies” include, but are not limited to, nanobodies or single-domain antibodies such as single-variable-domain antibodies, which are structures that contain only one variable region that selectively and preferably specifically binds to an antigen or target independently of other variable regions or domains, and which may be VH or VL. Since they are defined as containing VH and VL regions, not all of the above fragments are applicable to the first target antigen-binding domain, but they are applicable to embodiments relating to at least one further binding domain. Further possible forms included in the polypeptide / polypeptide constructs according to the present invention are crossbodies, maxibodies, hetero-Fc constructs, mono-Fc constructs and scFc constructs. Examples of these forms are described below herein.
[0010] Furthermore, the definition of the term “polypeptide construct” includes divalent and polyvalent / multivalent polypeptide / polypeptide constructs, as well as bispecific and polyspecific / multispecific polypeptide / polypeptide constructs that selectively and preferably specifically bind to two, three, or more antigenic structures (epitopes) via different binding domains. For example, if a polypeptide construct has two binding domains for one target (CD3 epsilon) and one binding domain for another target, e.g., one described herein, or vice versa, the polypeptide construct may have a binding value greater than its specificity, and in either case, the polypeptide construct is trivalent and bispecific. Generally, the term “bispecificity” includes the meaning that the polypeptide construct binds to at least two different antigens, e.g., preferably CD3 and further target antigens, preferably tumor antigens, e.g., those identified later herein.
[0011] The terms “paratope,” “antigen-binding domain,” “epitope-binding domain,” “binding domain,” or “domain that binds to ~” in relation to the present invention characterize a domain of a construct that selectively and preferably specifically or immunospecifically binds to an epitope on a target or target antigen, selectively and preferably specifically or immunospecifically interacts with said epitope, or selectively and preferably specifically or immunospecifically recognizes said epitope. The terms “binding domain,” “domain that binds to ~,” or “domain” in relation to the present invention characterize a domain of a construct that immunospecifically binds to an epitope on a target or target antigen, immunospecifically interacts with said epitope, or immunospecifically recognizes said epitope. The structure and function of the first binding domain (referred to as the first binding domain in the case of a polypeptide / polypeptide construct containing further, consequently second, third, etc., binding domains), and preferably the structure and / or function of any further binding domains (e.g., those that bind to target antigens such as cell surface antigens, preferably tumor antigens), are also based on the structure and / or function of the antibody, e.g., a full-length immunoglobulin polypeptide. Thus, the “binding domain” or “domain that binds to ~” may include the minimum structural requirements of the antibody that enable immune-specific target binding. The structural requirements of the first binding domain are specified to include VH and VL regions having three corresponding CDRs per region, but the minimum structural requirements in any further binding domain may be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2, and CDR3 in the VH region), preferably all six CDRs. A "binding domain" (or "binding domain") typically includes, but does not need to include, both the antibody light chain variable region (VL) and the antibody heavy chain variable region (VH), and may include only either VH or VL unless otherwise defined. The Fd fragment often retains some antigen-binding function of, for example, an intact antigen-binding domain.The terms “paratope,” “antigen-binding structure,” and “epitope-binding structure,” as used herein, also refer to a portion of an antibody (or molecule according to the present invention) that includes a region that specifically binds to and is complementary to all or part of an antigen or a portion thereof, i.e., the antibody can bind to only a specific portion of the antigen. The specific portion is called an “epitope.” The antigen-binding domain can be provided from one or more antibody variable domains. Preferably, the antigen-binding domain contains an antibody variable region that includes both an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). Examples of such preferred antigen-binding domains include “single-chain Fv(scFv),” “single-chain antibody,” “Fv,” “single-chain Fv2(scFv2),” “Fab,” and “F(ab')2.” According to the present invention, the first binding domain takes the form of scFv.
[0012] Examples of the forms "~binding domain," "paratope-containing domain" (or "binding domain," "antigen-binding structure," "epitope-binding structure"), unless otherwise defined, include, but are not limited to, the following: full-length antibody, fragments of full-length antibody (e.g., VH, VHH, VL), (s)dAb, Fv, light chain (VL-CL), Fd(VH-CH1), heavy chain, Fab, Fab', F(ab')2, or "r IgG ("half-antibody"), antibody variants or antibody derivatives, e.g., scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabody, single-chain diabody, tandem diabody (Tandab), tandem di-scFv, tandem tri-scFv, "minibody" (selected from forms such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2), multibody (e.g., triabody or tetrabody), and single-domain antibodies (e.g., nanobody or single-variable-domain antibody containing only one variable region which may be VHH, VH, or VL). In this specification, the first binding domain is defined as scFv such that some of the above forms may relate only to at least further binding domains that may be included in the polypeptide or polypeptide construct of the present invention. Further examples of the form "~binding domain" (or "binding domain") include: (1) antibody fragments or antibody variants containing VL, VH, CL, and CH1 (e.g., Fab); (2) antibody fragments or antibody variants containing two linked Fab fragments (e.g., F(ab')2); (3) antibody fragments or antibody variants containing VH and CH1 (e.g., Fd); (4) antibody fragments or antibody variants containing VL and CL (e.g., light chain); (5) antibody fragments or antibody variants containing VL and VH (e.g., Fv); (5) dAb fragments having a VH domain (Ward et al., (1989) Nature 341:544-546); (6) antibody variants containing at least three isolated CDRs of heavy chain and / or light chain; and (7) single-chain Fv (scFv).Examples of embodiments of the constructs or binding domains according to the present invention are described, for example, in International Publication No. 00 / 006605, International Publication No. 2005 / 040220, International Publication No. 2008 / 119567, International Publication No. 2010 / 037838, International Publication No. 2013 / 026837, International Publication No. 2013 / 026833, U.S. Patent Application Publication No. 2014 / 0308285, U.S. Patent Application Publication No. 2014 / 0302037, International Publication No. 2014 / 144722, International Publication No. 2014 / 151910, and International Publication No. 2015 / 048272. In relation to the present invention, a paratope is understood to be a part of the polypeptide described herein and an antigenic site that recognizes and binds to an antigen. A paratope is typically a small region of at least about five amino acids. Paratopes as understood herein typically include portions of the heavy chain (VH) and light chain (VL) sequences derived from an antibody. Each binding domain of the polypeptide according to the present invention comprises a paratope containing three sets of six complementarity-determining regions (CDR loops) contained within the antibody-derived VH and VL sequences.
[0013] With respect to compounds, particularly constructs of the present invention, a) the construct is a single-chain polypeptide or a single-chain polypeptide construct; b) the first binding domain is in the form of scFv; c) any further, e.g., a second binding domain and / or a third domain is in the form of scFv; d) the first and the further, e.g., the second and / or third domains are linked via a linker, preferably a peptide linker, e.g., a glycine / glutamine linker as defined herein; and / or e) the construct is envisioned to include a domain that provides an extension of the serum half-life, e.g., an Fc-based domain or human serum albumin (HSA). Specific forms of the corresponding compounds will be described later herein. In the latter case, i.e., with respect to the HLE domain, in which its presence is a preferred embodiment, the term “polypeptide construct” clarifies that it may include multiple single peptide chains. The preferred Fc-based domain (also called the "HLE" domain) that extends the serum half-life comprises two polypeptide monomers, each containing a hinge, a CH2 domain, and a CH3 domain, which are fused to each other via a peptide linker, in the form hinge-CH2-CH3-linker-hinge-CH2-CH3 from N-terminus to C-terminus.
[0014] The constructs of the present invention are preferably “in vitro-generated constructs” and / or “recombinant constructs.” In relation to the present invention, the term “in vitro-generated” refers to a construct as defined above, in which all or part of the binding domain or variable region (e.g., at least one CDR) is generated by non-immune cell selection on a protein chip, e.g., in vitro phage display, or any other method that allows a candidate amino acid sequence to be tested for its ability to bind to an antigen. Thus, the term preferably excludes sequences that are generated only by genomic rearrangement in animal immune cells. The first and / or second domains of the construct are assumed to be produced or obtainable by phage display or library screening, rather than by transplanting a CDR sequence from an existing (monoclonal) antibody onto a scaffold. “Recombinant constructs” are constructs generated or manufactured using (among other) recombinant DNA technology or genetic engineering.
[0015] The constructs of the present invention are assumed to be monoclonal. As used herein, a polypeptide or construct referred to as “monoclonal” (mAb) is obtained from a substantially homogeneous population of antibodies / constructs, i.e., the individual antibodies / constructs in this population are identical (particularly with respect to their amino acid sequence) except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in trace amounts. Monoclonal antibodies / constructs are highly specific, targeting a single epitope within an antigen, in contrast to polyclonal antibody preparations, which typically contain different antibodies targeting different determinants (or epitopes). In addition to this specificity, monoclonal antibodies are advantageous because they are synthesized by hybridoma culture and are therefore free from contamination by other immunoglobulins. The modifier “monoclonal” indicates a characteristic of antibodies / constructs obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring antibody production by any particular method.
[0016] For the preparation of monoclonal antibodies, any technique that provides antibodies produced by serial cell line culture can be used. For example, the monoclonal antibodies used may be produced by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or by the recombinant DNA method (see, for example, U.S. Patent No. 4,816,567). Further examples of techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96).
[0017] Next, hybridomas can be screened using standard methods such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (BIACORE®) analysis to identify one or more hybridomas that produce antibodies that selectively and, preferably specifically or immunospecifically, bind to a particular antigen. For example, any form of the relevant antigen can be used as an immunogen, such as recombinant antigen, its naturally occurring form, any variant or fragment thereof, and their antigenic peptides. Surface plasmon resonance, as employed in the BIAcore® system, can be used to enhance the efficiency of phage antibody / construct binding to the epitope of the target antigen (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).
[0018] Another exemplary method for constructing constructs or binding domains is the screening of protein expression libraries, such as phage display or ribosome display libraries. Phage display is described, for example, in Ladner et al., U.S. Patent No. 5,223,409; Smith (1985), Science 228:1315-1317; Clackson et al., Nature, 352:624-628 (1991); and Marks et al., J.Mol.Biol., 222:581-597 (1991).
[0019] In addition to using display libraries, non-human animals, such as rodents (e.g., mice, hamsters, rabbits, or rats), can be immunized using relevant antigens. In one embodiment, the non-human animal contains at least a portion of the human immunoglobulin gene. For example, a mouse strain lacking mouse antibody production can be modified using a large fragment of the human Ig (immunoglobulin) locus. Using hybridoma technology, antigen-specific monoclonal antibodies derived from genes with desired specificity can be produced and selected. See, for example, Xenomouse®, Green et al. (1994) Nature Genetics 7:13-21, U.S. Patent Application Publication No. 2003-0070185, International Publication No. 96 / 34096 and International Publication No. 96 / 33735.
[0020] Monoclonal antibodies can also be obtained from non-human animals and then modified, for example, by humanization, deimmunization, chimerization, etc., using recombinant DNA techniques known in the art. Examples of modified constructs or binding domains include humanized variants of non-human antibody / constructs, "affinity-matured" constructs or binding domains (see, e.g., Hawkins et al. J. Mol. Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody variants or mutants with altered effector function (see, e.g., U.S. Patent No. 5,648,260, Kontermann and Duebel (2010) and Little (2009) cited above).
[0021] In immunology, affinity maturation is the process by which B cells produce antibodies with increased affinity to an antigen during the course of an immune response. Repeated exposure to the same antigen causes the host to continuously produce antibodies with higher affinity. Similar to natural prototypes, in vitro affinity maturation is based on the principles of mutation and selection. In vitro affinity maturation has been successfully used to optimize antibodies, antibody fragments, antibody variants, constructs, or binding domains. Random mutations within CDRs are introduced using radiation, chemical mutagens, or error-prone PCR. In addition, genetic diversity can be increased by chain shuffling. Two or three mutations and selections using display methods such as phage display typically yield antibodies, antibody fragments, antibody variants, constructs, or binding domains with affinity in the low nanomolar concentration range.
[0022] Preferred types of amino acid substitution mutations for the constructs or binding domains of the present invention involve substituting one or more residues within the hypervariable region of the parental antibody structure (e.g., a humanized antibody or human antibody structure). Generally, the resulting one or more mutants selected for further development have improved biological properties compared to the parental antibody structure from which they were generated. A simple method for producing such substitution mutants involves affinity maturation using phage display. Briefly, several sites (e.g., 6-7 sites) in the hypervariable region are mutated to generate all possible amino acid substitutions at each site. The mutants thus generated are presented in a monovalent state from filamentous phage particles as fusions with the M13 gene III product packaged within each particle. The phage-presented mutants are then screened for their biological activity (e.g., binding affinity) as disclosed herein. Alanine scanning mutagenesis can also be performed to identify candidate hypervariable region sites (candidates for modification) that significantly contribute to antigen binding. Alternatively, or in addition, analysis of the crystal structure of the complex between the antigen and the construct or binding domain may be useful for identifying contact points between the binding domain and its specific antigen. Such contact residues and adjacent residues are candidates for substitution by the techniques detailed herein. Once such variants are generated, a panel of variants may be subjected to screening as described herein, and antibodies, their antigen-binding fragments, constructs, or binding domains exhibiting superior properties in one or more relevant assays may be selected for further development.
[0023] The constructs and binding domains of the invention specifically include "chimeric" versions, in which part of the heavy and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments or variants of such antibodies, so long as the desired biological activity is exhibited (U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric constructs or binding domains for the purposes herein include "primatized" constructs that include variable domain antigen-binding sequences derived from non-human primates (e.g., Old World monkeys, apes, etc.) and human constant region sequences. A variety of techniques for making chimeric antibodies or constructs are described. See, e.g., Morrison et al., Proc. Natl. Acad. Sci. U.S.A. 81:6851, 1985; Takeda et al., Nature 314:452, 1985; Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent No. 4,816,397; Tanaguchi et al., European Patent No. 0171496, European Patent No. 0173494, and British Patent No. 2177096.
[0024] Antibodies, polypeptide constructs, antibody fragments, antibody variants, or binding domains can also be modified by specific deletion of human T cell epitopes (a method called "deimmunization") using methods disclosed, for example, in International Publication No. 98 / 52976 or International Publication No. 00 / 34317. In short, the heavy and light chain variable regions of antibodies, constructs, or binding domains can be analyzed with respect to peptides that bind to MHC class II. These peptides correspond to potential T cell epitopes (as defined, for example, in International Publication No. 98 / 52976 and International Publication No. 00 / 34317). For the detection of potential T cell epitopes, a computer modeling technique called "peptide threading" can be applied, as described in International Publication No. 98 / 52976 and International Publication No. 00 / 34317, and in addition, motifs present in VH and VL sequences can be searched in databases of human MHC class II binding peptides. These motifs bind to any of the 18 major MHC class I DR allotypes and thus constitute potential T cell epitopes. Detected potential T cell epitopes can be removed by substitution of a few amino acid residues within a variable domain or variable region, or preferably by single amino acid substitution. Typically, conservative substitutions are performed. In many cases, but not limited to, amino acids common to the position in human germline antibody sequences may be used. Human germline sequences are disclosed, for example, in Tomlinson, et al. (1992) J.Mol.Biol.227:776-798; Cook, GP et al. (1995) Immunol.Today Vol.16(5):237-242; and Tomlinson et al. (1995) EMBO J.14:14:4628-4638. The V BASE directory (www2.mrc-lmb.cam.ac.uk / vbase / list2.php) provides a comprehensive overview of human immunoglobulin variable region sequences (edited by Tomlinson, LA. et al., MRC Centre for Protein Engineering, Cambridge, UK).These arrays can be used, for example, as a source of human sequences for the framework regions and CDRs. For example, the consensus human framework region described in U.S. Patent No. 6,300,064 can also be used.
[0025] "Humanized" antibodies, their variants or fragments, constructs and binding domains are primarily based on human immunoglobulin sequences, which contain minimal sequences derived from non-human immunoglobulins. In most cases, the humanized antibody, its variant or fragment, construct and binding domain are based on a human immunoglobulin (recipient antibody), in which residues from the hypervariable regions or CDRs are replaced with residues from the hypervariable regions or CDRs of a non-human species (donor antibody) such as a rodent (e.g., mouse, hamster, rat or rabbit) having the desired specificity, affinity, potency and / or biological activity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced with the corresponding non-human residues. Furthermore, "humanized" antibodies, their variants or fragments, constructs and binding domains as used herein may also include residues not found in either the recipient antibody or the donor antibody. These modifications are made to further improve and optimize the performance of the antibody. The humanized antibody, its variant or fragment, construct and binding domain may also include at least a portion of the immunoglobulin constant region (e.g., Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).
[0026] Humanized antibodies, their variants or fragments, constructs, and binding domains can be created by replacing the sequence of the non-antigen-binding (Fv) variable region with an equivalent sequence from the human (Fv) variable region. Exemplary methods for generating such molecules are provided by Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214, and U.S. Patents 5,585,089, 5,693,761, 5,693,762, 5,859,205, and 6,407,213. These methods involve isolating, manipulating, and expressing nucleic acid sequences encoding all or part of the immunoglobulin (Fv) variable region from at least one of the heavy or light chains. Such nucleic acids can be obtained, as described above, from hybridomas producing antibodies against a given target, as well as from other sources. Next, recombinant DNA encoding a humanized antibody, its variant or fragment, construct, or binding domain can be cloned into a suitable expression vector.
[0027] Humanized antibodies, their variants or fragments, constructs, and binding domains can also be prepared using transgenic animals (e.g., mice) that express human heavy and light chain genes but lack the ability to express endogenous mouse immunoglobulin heavy and light chain genes. Winter describes exemplary CDR grafting methods that can be used for the preparation of the humanized molecules described herein (U.S. Patent No. 5,225,539). All of the CDRs of a given human sequence may be replaced with at least some of the non-human CDRs, or only some of the CDRs may be replaced with non-human CDRs. It is sufficient to replace only the number of CDRs necessary for the humanized molecule to bind to a given antigen.
[0028] Humanized antibodies, their variants or fragments, constructs, or binding domains can be optimized by introducing conservative substitutions, consensus sequence substitutions, germline substitutions, and / or reverse mutations. Such modified immunoglobulin molecules can be prepared by any of several techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. USA, 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:7279, 1983; Olsson et al., Meth. Enzymol., 92:3-16, 1982; and European Patent No. 239400).
[0029] Human anti-mouse antibody (HAMA) responses have led the industry to prepare chimeric antibodies or other humanized antibodies / constructs. However, certain human anti-chimeric antibody (HACA) reactions are expected to be observed, particularly in chronic or high-dose use of antibodies or constructs. Therefore, it would be desirable to provide constructs containing human-binding domains to targets in order to eliminate concerns and / or effects of HAMA or HACA reactions.
[0030] Therefore, according to one embodiment, the polypeptide construct has at least one further binding domain, the binding domain of which is “human.” The terms “human antibody,” “human construct,” and “human binding domain” include antibodies, constructs, and binding domains having antibody-derived regions such as variable regions and constant regions or domains, respectively, which substantially correspond to human germline immunoglobulin sequences known in the art, including, for example, those described by Kabat et al. (1991) (cited above). The human construct or binding domain of the present invention may include amino acid residues not encoded by the human germline immunoglobulin sequence (e.g., mutations introduced in vitro by random or site-directed mutagenesis, or in vivo by somatic mutation), for example, in the CDR, particularly CDR3. The human construct or binding domain may have at least one, two, three, four, five or more positions replaced by amino acid residues not encoded by the human germline immunoglobulin sequence. The definitions of human antibodies, constructs, and binding domains used herein also refer to fully human antibodies, constructs, and binding domains that consist solely of human sequences that have not been artificially and / or genetically modified, such as those that can be derived using technologies or systems such as Xenomouse.
[0031] Polypeptides / polypeptide constructs containing at least one human-binding domain avoid some of the problems associated with antibodies or constructs that have non-human variable and / or constant regions, such as those derived from rodents (e.g., mice, rats, hamsters, or rabbits). The presence of such rodent-derived proteins may lead to rapid clearance of the antibody or construct, or to an immune response by the patient to the antibody or construct. To avoid the use of rodent-derived constructs, humanized or fully human constructs can be created by introducing human antibody function into rodents so that the rodents produce fully human antibodies.
[0032] The ability of YAC to clone and reconstruct megabase-sized human loci and to introduce them into mouse germline cells provides a powerful method for elucidating the functional elements of very large or coarsely mapped loci and for creating useful models of human diseases. Furthermore, the use of such techniques to replace mouse loci with their human equivalents can provide unique insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.
[0033] A key practical application of such strategies is the "humanization" of the mouse humoral immune system. Introducing human Ig loci into mice with inactivated endogenous immunoglobulin (Ig) genes provides an opportunity to study the programmed expression and construction of antibodies, as well as the underlying mechanisms of their role in B cell development. Furthermore, such strategies could provide an ideal source for producing fully human monoclonal antibodies (mAbs), a crucial milestone in realizing the potential of antibody therapy in human diseases. Fully human antibodies or their constructs are expected to minimize the immunogenicity and allergic reactions inherent in mouse mAbs or mouse-derived mAbs, thereby increasing the efficacy and safety of the administered antibody / construct. The use of fully human antibodies or constructs is anticipated to offer substantial advantages in the treatment of chronic and recurrent human diseases requiring repeated administration of compounds, such as inflammation, autoimmunity, and cancer.
[0034] One approach to this goal was to manipulate mouse strains lacking mouse antibody production using large fragments of the human Ig locus, anticipating that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve significant variable gene diversity as well as appropriate regulation of antibody production and expression. By leveraging mouse mechanisms for antibody diversification and selection, and the lack of immune tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should produce high-affinity antibodies against any target antigen, including human antigens. Using hybridoma technology, antigen-specific human mAbs with desired specificity could be easily produced and selected. This general strategy was demonstrated in connection with the development of the first XenoMouse mouse strain (see Green et al. Nature Genetics 7:13-21 (1994)). This XenoMouse strain was engineered using yeast artificial chromosomes (YACs) containing germline arrangement fragments of 245kb and 190kb sizes, respectively, of the human heavy chain locus and kappa light chain locus, containing the core sequences of the variable and constant regions. Human Ig containing YACs proved compatible with the mouse strain for both antibody rearrangement and expression, and was able to replace inactivated mouse Ig genes. This was demonstrated by their ability to induce B cell development to produce an adult-like human repertoire of fully human antibodies and antigen-specific human mAbs. These results also suggested that the introduction of a large portion of the human Ig locus, containing numerous V genes, additional regulatory elements, and the human Ig constant region, could reproduce a substantially complete repertoire characterized by the human humoral response to infection and immunization. The study by Green et al. extended to the introduction of over 80% of the human antibody repertoire by introducing megabase-sized germline arrangement YAC fragments of the human heavy chain locus and kappa light chain locus, respectively. See Mendez et al. Nature Genetics 15:146-156 (1997) and U.S. Patent Application Publication No. 08 / 759,620.
[0035] The XenoMouse model was created using U.S. Patent Publication Nos. 07 / 466,008, 07 / 610,515, 07 / 919,297, 07 / 922,649, 08 / 031,801, 08 / 112,848, 08 / 234,145, 08 / 376,279, 08 / 430,938, 08 / 464,584, 08 / 464,582, 08 / 463,191, 08 / 462,837, and 08 / 4 This is further discussed and detailed in Patent No. 86,853, Patent No. 08 / 486,857, Patent No. 08 / 486,859, Patent No. 08 / 462,513, Patent No. 08 / 724,752, Patent No. 08 / 759,620, and U.S. Patents No. 6,162,963, No. 6,150,584, No. 6,114,598, No. 6,075,181, and No. 5,939,598, as well as in Japanese Patent Publication No. 3068180B2, No. 3068506B2, and No. 3068507B2. See also Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovits J. Exp. Med. 188:483-495 (1998), European Patent No. 0463151B1, International Publication No. 94 / 02602, International Publication No. 96 / 34096, International Publication No. 98 / 24893, International Publication No. 00 / 76310, and International Publication No. 03 / 47336.
[0036] Another approach, particularly that used by other companies including GenPharm International, Inc., is the "minilocus" approach. In the minilocus method, an exogenous Ig locus is mimicked by including fragments (individual genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a μ constant region, and a second constant region (preferably a γ constant region) are formed as an insertion construct into the animal. This method is based on U.S. Patent No. 5,545,807 to Surani et al., and U.S. Patents No. 5,545,806, No. 5,625,825, No. 5,625,126, No. 5,633,425, No. 5,661,016, No. 5,770,429, No. 5,789,650, No. 5,814,318, No. 5,877,397, No. 5,874,299, and No. 6,255,458 to Lonberg and Kay, respectively, and U.S. Patents No. 5,591,669 and No. 6,023,010 to Krimpenfort and Berns, and Berns et al. U.S. Patent Nos. 5,612,205, 5,721,367 and 5,789,215 against al., and U.S. Patent No. 5,643,763 against Choi and Dunn, and GenPharm This is described in U.S. Patent Publication Nos. 07 / 574,748, 07 / 575,962, 07 / 810,279, 07 / 853,408, 07 / 904,068, 07 / 990,860, 08 / 053,131, 08 / 096,762, 08 / 155,301, 08 / 161,739, 08 / 165,699, and 08 / 209,741 of International.See also European Patent No. 0546073B1, International Publication No. 92 / 03918, International Publication No. 92 / 22645, International Publication No. 92 / 22647, International Publication No. 92 / 22670, International Publication No. 93 / 12227, International Publication No. 94 / 00569, International Publication No. 94 / 25585, International Publication No. 96 / 14436, International Publication No. 97 / 13852 and International Publication No. 98 / 24884, and U.S. Patent No. 5,981,175. Furthermore, see Taylor et al. (1992), Chen et al. (1993), Tuaillon et al. (1993), Choi et al. (1993), Lonberg et al. (1994), Taylor et al. (1994), and Tuaillon et al. (1995), and Fishwild et al. (1996).
[0037] Kirin has also demonstrated the production of human antibodies from mice by introducing large chromosome fragments or entire chromosomes via microcell fusion. See European Patent Publications No. 773288 and 843961. Xenerex Biosciences is developing a technology for the potential production of human antibodies. This technology involves reconstituting SCID mice with human lymphocytes, such as B cells and / or T cells. The mice can then be immunized with an antigen to induce an immune response to the antigen. See U.S. Patents No. 5,476,996, 5,698,767 and 5,958,765.
[0038] In some embodiments, the constructs of the present invention are “isolated” or “substantially pure” constructs. “Isolated” or “substantially pure,” as used in the description of constructs disclosed herein, means a construct that has been identified, separated, and / or recovered from the components of its production environment. Preferably, the construct is unrelated, or substantially unrelated, to all other components from its production environment. Contaminating components of its production environment, such as those arising from recombinant transfected cells, are materials that may interfere with the diagnostic or therapeutic use of the construct and include enzymes, hormones, and other proteinaceous or non-proteinaceous compounds. It is understood that isolated or substantially pure constructs may, depending on the context, account for 5% to 99.9% by weight of the total protein / polypeptide content in a given sample. The desired construct may be produced at significantly higher concentrations using an inducible promoter or a high-expression promoter. The definitions include the production of constructs in a wide variety of organisms and / or host cells known in the art. In certain embodiments, the construct is purified to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence by (1) using a spinning cup sequencer, or to a degree of homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or preferably silver staining. However, typically, the isolated construct is prepared by at least one purification step.
[0039] According to one embodiment, the entire construct and / or the binding domain is in the form of one or more polypeptides or proteins. In addition to the proteinaceous portion, such polypeptides or proteins may include non-proteinaceous portions (e.g., chemical linkers or chemical crosslinking agents, e.g., glutaraldehyde).
[0040] Peptides are short chains of amino acid monomers linked by covalent peptide (amide) bonds. Therefore, peptides are classified into a broad chemical class of biological oligomers and polymers. Amino acids that are part of a peptide or polypeptide chain are called "residues" and can be sequentially numbered. All peptides except cyclic peptides have an N-terminal residue at one end and a C-terminal residue at the other. Oligopeptides consist of a very small number of amino acids (usually 2 to 20). Polypeptides are longer, continuous, unbranched peptide chains. Peptides are distinguished from proteins based on size and, as an arbitrary criterion, can be understood as containing approximately 50 or fewer amino acids. Proteins typically consist of one or more polypeptides arranged in a biologically functional manner. While the aspects of experimental techniques applied to peptides, polypeptides, and proteins differ (e.g., details of electrophoresis, chromatography, etc.), the size boundary distinguishing peptides from polypeptides and proteins is not absolute. Therefore, in the context of this invention, the terms "peptide," "polypeptide," and "protein" can be used interchangeably, and the term "polypeptide" is often preferred.
[0041] Polypeptides, as described above, can further form polymers such as dimers, trimers, and higher-order oligomers, consisting of two or more polypeptide molecules. The polypeptide molecules forming such dimers, trimers, etc., may or may not be identical. The corresponding higher-order structures of such polymers are consequently referred to as homodimers or heterodimers, homotrimers or heterotrimers, etc. An example of a heteropolymer is an antibody or immunoglobulin molecule, in its naturally occurring form, consisting of two identical polypeptide light chains and two identical polypeptide heavy chains. The terms “peptide,” “polypeptide,” and “protein” also refer to naturally modified peptides / polypeptides / proteins, where modifications are achieved by post-translational modifications such as glycosylation, acetylation, or phosphorylation. “Peptides,” “polypeptides,” or “proteins,” as used herein, may also be chemically modified, such as pegylation. Such modifications are well known in the art and will be described later herein.
[0042] The terms “selectively,” “preferably selectively,” “to bind to (specifically or immunospecifically),” “to recognize (specifically or immunospecifically),” or “to react with (specifically or immunospecifically)” mean, in accordance with the present invention, that a construct or binding domain selectively or (immunologically) specifically interacts with a target molecule (antigen), e.g., a given epitope on CD3. This selective interaction or association occurs more frequently, more rapidly, for longer durations, with higher affinity, or with some combination of these parameters, to an epitope on a particular target (e.g., CD3 epsilon) compared to an alternative substance (a non-target molecule, e.g., CD3 gamma as herein). However, due to sequence similarities between homologous proteins in different species, a construct or binding domain that selectively and / or immunospecifically binds to a target (e.g., a human target) may cross-react with homologous target molecules from different species (e.g., non-human primates). Therefore, terms such as “selectively binding to” and “specific / immunospecific binding” may include the binding of a construct or binding domain to two or more species of epitopes or structurally related epitopes. In relation to the present invention, the polypeptides of the present invention bind to their respective target structures in a specific manner. Preferably, the polypeptides according to the present invention include one paratope per binding domain that “specifically or immunospecifically binds to” or “recognizes” or “reacts” with each target structure. This means that, according to the present invention, the polypeptide or its binding domain interacts with or (immuno)specifically with a given epitope on a target molecule (antigen), e.g., CD3 epsilon, and in certain embodiments, interacts with a given epitope on at least one further target molecule, such as a second and / or third target molecule. This interaction or association occurs more frequently, more rapidly, for longer durations, with greater affinity, or with some combination of these parameters, towards an epitope on a specific target compared to an alternative substance (non-target molecule).However, due to sequence similarities between homologous proteins in different species, antibody constructs or binding domains that immunospecifically bind to targets (such as human targets) may cross-react with homologous target molecules from different species (such as non-human primates). Therefore, the term “specific / immunospecific binding” may include the binding of antibody constructs or binding domains to epitopes and / or structurally related epitopes in multiple species. The term “(immuno)selective binding” excludes binding to structurally related epitopes within a single species.
[0043] In the context of this invention, the term “epitope” refers to a portion or region of an antigen that is selectively recognized / immunospecifically by a binding structure, i.e., a paratope. “Epitope” is antigenic, and therefore the term “epitope” may also be referred to herein as “antigenic structure” or “antigenic determinant.” The portion of the binding domain that binds to an epitope is called a paratope. Specific binding is thought to be achieved by the binding domain and specific motifs in the amino acid sequence of the antigen. Thus, binding is achieved due to their primary, secondary, and / or tertiary structures, as well as as a result of potential secondary modifications of such structures. When a paratope specifically interacts with its antigenic determinant, the site may simply bind to the antigen. In some cases, instead or in addition, specific interactions may result in signal initiation, for example, due to the induction of conformational changes of the antigen, oligomerization of the antigen, etc.
[0044] Epitopes of protein antigens are classified into two categories based on their structure and interaction with paratopes: conformational epitopes and linear epitopes. Conformational epitopes consist of discontinuous sections of the antigen's amino acid sequence. These epitopes interact with paratopes based on the characteristics and shape or tertiary structure (folding) of the antigen's three-dimensional surface. Methods for determining the conformation of an epitope include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy. In contrast, linear epitopes interact with paratopes based on their primary structure. Linear epitopes are formed by a continuous sequence of amino acids derived from the antigen and typically contain at least three or at least four, more commonly at least five, at least six, or at least seven, for example, about 8 to about 10 amino acids within a specific sequence.
[0045] A method for epitope mapping for a given human target protein is described below. A predetermined region (a continuous amino acid stretch) within the given human target protein is exchanged / replaced with the corresponding region of the target protein paralog (unless the binding domain cross-reacts with the paralog used). These human target / paralog chimeras are expressed on the surface of host cells (e.g., CHO cells). Binding of an antibody or construct can be tested via FACS analysis. If the binding of the antibody or construct to this chimeric molecule is completely absent or a significant decrease in binding is observed, it can be concluded that the region of the human target removed from this chimeric molecule is associated with immunospecific epitope-paratope recognition. The decrease in binding is preferably at least 10%, 20%, 30%, 40%, or 50%, more preferably at least 60%, 70%, or 80%, most preferably 90%, 95%, or even 100%, compared to binding to the human (wild-type) target, thereby setting the binding to the human target to 100%. Alternatively, the epitope mapping analysis described above can be modified by introducing one or more point mutations into the sequence of a human target. These point mutations may, for example, reflect differences between the human target and its paralog.
[0046] A further method for determining the contribution of specific residues of a target antigen to recognition by a construct or binding domain is alanine scanning, in which each residue analyzed is replaced with alanine, for example, by site-directed mutagenesis (see, e.g., Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7). Alanine is used because it has a non-bulky, chemically inactive methyl functional group that still mimics the secondary structure criteria of many other amino acids. If size preservation of the mutated residue is desired, bulkier amino acids such as valine or leucine may be used.
[0047] The interaction between the binding domain and the epitope of the target antigen implies that the binding domain is recognizable or exhibits significant affinity to the epitope / target antigen, and generally does not exhibit significant affinity to proteins or antigens other than the target antigen, even if there is cross-reactivity with homologous targets from other species, as discussed above. "Significant affinity" refers to binding with an affinity (dissociation constant (KD)) of ≤10⁻⁶ M. Preferably, binding is considered specific when the binding affinity is ≤10⁻⁷ M, ≤10⁻⁸ M, ≤10⁻⁹ M, or even ≤10⁻¹¹ M, or ≤10⁻¹² M. Whether a binding domain reacts (immunologically) specifically with a target or binds (immunologically) specifically to a target can be easily tested, for example, by comparing the affinity of the binding domain to the desired target protein or antigen with the affinity of the binding domain to a non-target protein or antigen. Preferably, the construct of the present invention does not significantly bind to proteins or antigens other than the target antigen unless any further binding domains for further targets are intentionally introduced into the construct of the present invention, in which case the binding of such binding domains to their specific targets is also provided by the present invention.
[0048] The affinity of the first domain is assumed to be ≤100 nM, ≤90 nM, ≤80 nM, ≤70 nM, ≤60 nM, ≤50 nM, ≤40 nM, ≤30 nM, or ≤20 nM. These values are preferably measured by cell-based assays, such as the scatchard assay. Other affinity determination methods are also known. These values are preferably measured by surface plasmon resonance assays, such as the Biacore assay.
[0049] The terms "significantly inactive" and "selectively inactive" mean that, when the construct or binding domain of the present invention is expressed on the surface of a cell, it does not bind to any protein or antigen other than the target antigen. Therefore, the construct exhibits reactivity with any protein or antigen other than the target antigen (when the protein or antigen is expressed on the surface of a cell) of ≤30%, preferably ≤20%, more preferably ≤10%, and particularly preferably ≤9%, ≤8%, ≤7%, ≤6%, ≤5%, ≤4%, ≤3%, ≤2%, or ≤1%, thereby setting the binding to the target antigen to 100%, respectively. "Reactivity" can be expressed, for example, by affinity values (see above).
[0050] It is assumed that the construct of the present invention (more specifically, a domain containing a paratope / binding domain that binds to the first target antigen) will not bind to the target antigen paralog, or will not bind significantly. It is also assumed that the construct will not bind to the (human or macaque / cynomolgus monkey) target antigen paralog on the surface of the target cell, or will not bind significantly.
[0051] The peptide linkers are S(G4X)n and (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20. Preferably, X is selected from amino acids having polar uncharged side chains, i.e., Q, T, N, and amino acids having hydrophobic side chains, i.e., A, V, I, L, and M. In another preferred embodiment, X is selected from Q, T, and N. The integer n is preferably selected from any integer in the range of 1-18, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-3, and 1-2, for example, integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18, preferably integers 1, 3, and 6. The corresponding linker sequences are defined in sequence numbers 2-77. Preferred linkers in sequence numbers 15, 34, 53, and 72 are also outlined below herein.
[0052] The (G4S)n or S(G4S)n linker (wherein n has the same definition as enumerated herein) used in the context of scFv as a standard peptide linker in the art, i.e., linking the VH region and the VL region, has been observed to be prone to clipping, and therefore impair the stability of these molecules or molecules containing the corresponding scFv. Replacing the G4S linker, i.e., the (G4S)n linker or S(G4S)n linker, with a linker as defined herein, preferably an S(G4Q)n linker or (G4Q)n linker, contributes to a reduction in the clipping rate (see the Examples section, e.g., Example 2, Figure 5, Table 1). For larger molecules, including regions beyond the VH and VL regions linked by the linker, other linkers, such as diabodies or (scFv)2, which link the binding domain within the BiTE® molecule, can also be replaced, potentially leading to a further reduction in the clipping rate, as shown in the Examples section. More specifically, molecular evaluation data for the BiTE® molecule showed that the percentage of low molecular weight (LMW) species, measured by reductive capillary electrophoresis (rCE-SDS) (a preferred means for evaluating the clipping rate), ranged from 16.6% to 24.1% for two exemplary BiTE® molecules after 4 weeks of incubation at 40°C (simulating 2 years of liquid storage at 4°C). Depending on the resulting LMW fragments, the pharmacokinetics of the BiTE molecule, such as the observed half-life in vivo or the efficacy and safety of the BiTE molecule, may potentially reduce its usefulness for patients. To better understand the factors contributing to the observed clipping levels, exemplary BiTE molecules (targeting PSMA and CD33) were generated using the following modifications: a G4Q linker (compared to the G4S linker of the standard BiTE HLE molecule), a stabilized CD3-binding domain (compared to the standard CD3-binding domain), introduction of an manipulated Cys clamp into the CD3-binding domain (compared to no Cys clamp), and / or removal of a specific single-stranded Fc(scFc)DP and hinge site (compared to standard scFc).To determine the effect of sequence variants on potency, all variants were tested for their in vitro activity compared to a reference control. In addition, BiTE molecular variants were incubated at 40°C for 4 weeks, and the overall proportion of LMW species was monitored using rCE-SDS. Site-specific clipping was monitored using peptide mapping. Introduced modifications were shown to significantly reduce overall clipping (introduction of a G4Q linker reduced the proportion of LMWs by 7.1%). Combinations of these modifications were shown to significantly reduce overall clipping of the BiTE molecule after pyrolysis. In addition, a stabilized CD3 binding domain, insertion of a G4Q linker, and CD3 Cys clamp modification all contribute to the reduction of clipping in the linker domain. Thus, linkers and further modifications as defined herein were demonstrated to reduce the appearance of LMWs due to clipping, i.e., to reduce the clipping rate. As such, liquid formulations of polypeptides or polypeptide constructs of the present invention are effective options due to the reduction in the clipping rate.
[0053] This specification will later outline which linkers should have the form of linkers as defined herein in order to improve the stability of a given polypeptide or polypeptide by reducing the clipping rate, including not only the scFv binding domain but also half-life extension domains which may be part of the polypeptide or polypeptide construct of the present invention. In other words, the present invention relates to a polypeptide or polypeptide construct comprising a single chain polypeptide or polypeptide construct comprising a first target antigen binding domain, wherein the first target antigen binding domain comprises VH and VL variable regions linked by a peptide linker, wherein the peptide linker comprises or comprises S(G4X)n and (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20, and the linker replaces S(G4S)n and (G4S)n linkers.
[0054] In preferred embodiments of the polypeptide or polypeptide construct of the present invention, the integer n is 1, 2, 3, 4, 5, or 6. The integer n is preferably 2, 3, 4, 5, or 6, or more preferably 1, 3, or 6.
[0055] In accordance with the present invention, X in S(G4X)n or (G4X)n is preferably Q. As such, the peptide linker is S(G4Q)n or (G4Q)n. Throughout the present invention as described herein, amino acid Q is a preferred amino acid for X. For example, the linker may be S(G4Q), S(G4Q)3, S(G4Q)6 or (G4Q), (G4Q)3 or (G4Q)6.
[0056] In preferred embodiments, the peptide linker of the polypeptide or polypeptide construct of the present invention is S(G4X)n or (G4X)n, where n is 3 and X is Q. Thus, the peptide linker has the form (G4Q)3 (SEQ ID NO: 15) or S(G4Q)3.
[0057] In accordance with the present invention, the polypeptide or polypeptide construct of the present invention may include at least one further binding domain that binds to a target antigen. As outlined above, the polypeptide or polypeptide construct of the present invention may include at least one further target antigen-binding domain and is therefore at least a bispecific molecule. According to one embodiment, the polypeptide construct of the present invention is a “single-chain construct” or “single-chain polypeptide.” In the case of the further binding domain, it is also conceivable that either or both of the first binding domain or the further binding domain (also called the “second”) may be in the form of a “single-chain Fv” (scFv). The two domains of the Fv fragment, VL and VH, are encoded by separate genes, but they can be linked by an artificial linker (as described above herein) which allows them to be constructed using recombination so that the VL and VH regions pair up to form a monovalent molecule (see, for example, Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883). These antibody fragments are obtained using prior art known to those skilled in the art, and the fragments are evaluated for function in the same manner as full-length antibodies or IgG. Therefore, single-chain variable fragments (scFv) are typically fusion proteins of the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin, linked by a short linker peptide. The linker is usually rich in glycine for flexibility and serine or even threonine for solubility, and can ligate the N-terminus of VH to the C-terminus of VL, or vice versa. Despite the removal of the constant region and the introduction of the linker, the protein retains the specificity of the original immunoglobulin.
[0058] Bispecific single-chain molecules are known in the art and are described in International Publication No. 99 / 54440, Mack, J. Immunol. (1997), 158, 3965-3970, Mack, PNAS, (1995), 92, 7021-7025, Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197, Loeffler, Blood, (2000), 95, 6, 2098-2103, Bruehl, Immunol., (2001), 166, 2420-2426, and Kipriyanov, J. Mol. Biol., (1999), 293, 41-56. The techniques described for producing single-chain constructs (in particular, U.S. Patent No. 4,946,778, Kontermann and Duebel (2010), cited above, and Little (2009), cited above) can be adapted to produce single-chain constructs that selectively, preferably specifically recognize a selected target.
[0059] Bivalent (also called divalent) or bispecific single-chain variable fragments (bi-scFv or di-scFv) having form (scFv)2 can be manipulated by linking two scFv molecules (using a linker as described herein). Linking can be done by creating a single polypeptide chain having two VH regions and two VL regions to produce a tandem scFv (see, e.g., Kufer P. et al., (2004) Trends in Biotechnology 22(5):238-244). Another possibility is the creation of scFv molecules using a linker peptide that is too short for the two variable regions to fold together (e.g., about 5 amino acids, less than 12 amino acids), forcing the scFv to dimerize. In this case, the VH and VL of the binding domain (which binds to either the first or further target antigen) are not directly linked via the peptide linker. Therefore, the VH of the first target antigen-binding domain may fused via a peptide linker to the VL of a further target antigen-binding domain, for example, as defined herein, and the VH of the further target antigen-binding domain is fused with the VL of the first binding domain via such peptide linker. This type is known as a diabody (see, for example, Hollinger, Philipp et al., (July 1993) Proceedings of the National Academy of Sciences of the United States of America 90(14):6444-8).In such a scenario, the first target antigen-binding domain of the main embodiment includes only half of the binding domain to the first target antigen, e.g., the VH region, whereas the remainder of the binding domain includes half of the binding domain to a second target antigen, e.g., the VL region, consistent with the present invention as relating to a polypeptide or polypeptide construct comprising at least two binding domains, wherein the binding domain is as defined herein, i.e., having the VH and VL regions, and includes at least one peptide linker linking the VH and VL regions as defined herein, i.e., the peptide linker comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20.
[0060] In accordance with the present invention, at least one further target antigen-binding domain comprises the same components as the first target antigen-binding domain. In this embodiment, the polypeptide or polypeptide construct comprises two binding domains, each having the form VH / VL-peptide linker-VH / VL. As outlined above in this specification, the corresponding polypeptide or polypeptide construct includes, for example, diabody and (scFv)2 molecules. In this specification, the notation VH / VL-peptide linker-VH / VL is understood to mean that both configurations are encompassed. That is, in the order of amino to carboxyl, the forms VH-peptide linker-VL and VL-peptide linker-VH are encompassed by the present invention.
[0061] In accordance with the present invention, each target antigen-binding domain binds to one target antigen. In this embodiment, each binding domain contains all the components that enable binding to only one target antigen, and therefore each binding domain includes VH and VL regions. In other words, the VH and VL variable regions of one target antigen-binding domain bind to the target, while the VH and VL variable regions of at least one further target antigen-binding domain bind to the target. Thus, this embodiment does not extend to a bispecific diabody in which two scFvs dimerize to form two binding domains resulting from the dimerization of two polypeptide chains as defined in the main embodiment. Instead, the polypeptide or polypeptide construct of the present invention is preferably (scFv)2. The following embodiments relate to different forms of scFv-based polypeptides or polypeptide constructs according to the present invention. In all of these embodiments and in accordance with the present invention, at least one binding domain is characterized by the presence of a peptide linker as defined herein, i.e., a peptide linker comprising or consisting of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20, the preferred embodiments thereof as described above herein. Furthermore, as described above herein, the S(G4X)n or (G4X)n substitutes S(G4S)n or (G4S)n in the different forms of the scFv-based polypeptide or polypeptide construct described below. Moreover, it is preferable that three or more, three or more, binding domains contained in the polypeptide or polypeptide construct of the present invention comprise the linker. As outlined above in this specification, the corresponding polypeptide or polypeptide construct of the present invention exhibits a reduced clipping rate compared to the corresponding, i.e., the same polypeptide or polypeptide construct using the latest serine / glycine linker technology.
[0062] In a preferred embodiment, the polypeptide or polypeptide construct of the present invention comprises: binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL). This embodiment relates to a single-chain polypeptide comprising two binding domains, where one or both peptide linkers are as defined herein above, i.e., the peptide linker comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20. Also, as outlined herein above, preferably the peptide linker is (G4Q)3, and preferably both peptide linkers in the binding domain are (G4Q)3. In other words, binding domain 1 and / or binding domain 2 include VH and VL variable regions linked by a peptide linker, which includes or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20, i.e., the binding domain is as defined herein above. As understood herein, the feature in parentheses, i.e., (VH / VL peptide linker-VH / VL), defines the structure of the binding domain.
[0063] Preferably, not only the first binding domain but also the at least one further binding domain binds to the cell surface antigen as a target antigen. As used herein, the term “cell surface antigen” refers to a molecule presented on the surface of a cell. In most cases, the molecule is located inside or on the cell’s plasma membrane such that at least a portion of the molecule remains accessible from outside the cell in its tertiary form. A non-limiting example of a cell surface molecule located inside the plasma membrane is a transmembrane protein that contains hydrophilic and hydrophobic regions in its tertiary conformation. Here, at least one hydrophobic region allows the cell surface molecule to be embedded in or inserted into the cell’s hydrophobic plasma membrane, while the hydrophilic region extends into the cytoplasm and extracellular space on either side of the plasma membrane, respectively. Non-exclusive examples of cell surface molecules located on the plasma membrane include proteins modified with cysteine residues to have a palmitoyl group, proteins modified with a C-terminal cysteine residue to have a farnesyl group, or proteins modified at the C-terminus to have a glycosylphosphatidylinositol ("GPI") anchor.
[0064] According to one embodiment of the paratope-containing binding domain described herein, the VH region is located at the N-terminus of the linker and the VL region is located at the C-terminus of the linker. In other words, in one embodiment of the paratope-containing binding domain described herein, scFv comprises VH-linker-VL from the N-terminus to the C-terminus. In accordance with the present invention, the paratope-containing binding domain of a construct described herein is bound via a peptide linker as defined herein by the present invention. The construct may comprise, for example, one binding domain-linker-further binding domain (from the N-terminus to the C-terminus). The reverse order (further binding domain-linker-first binding domain) is also possible.
[0065] In accordance with the present invention, the polypeptide or polypeptide construct comprises a binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-binding domain 3 (VH / VL-peptide linker-VH / VL).
[0066] In preferred embodiments of the polypeptide or polypeptide construct of the present invention, the C-terminal binding domain is bound to CD3, and the remaining N-terminal binding domain is bound to a cell surface antigen. Preferably, the polypeptide or polypeptide construct of the present invention is a T cell engager. Therefore, it is preferable that the polypeptide or polypeptide construct of the present invention comprises at least a CD3-binding domain and a cell surface antigen (preferably a tumor antigen)-binding domain, as defined later herein. Therefore, according to the present invention, the polypeptide or polypeptide or polypeptide construct comprises (preferably in the order from amino to carboxyl) the following: binding domain 1 (tumor antigen binding domain: VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (CD3 binding domain: VH / VL-peptide linker-VH / VL), wherein binding domain 1 binds to a cell surface antigen, preferably a tumor antigen, and binding domain 2 binds to CD3, preferably human CD3, more preferably human CD3 epsilon, or binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-binding domain 3 (CD3 binding domain: VH / VL-peptide linker-VH / VL), wherein binding domains 1 and 2 bind to the same or different cell surface antigen, preferably the same or different tumor antigen, and binding domain 3 binds to CD3, preferably human CD3, more preferably human CD3 epsilon. Preferably, binding domain 2 is linked to binding domain 3 via a linker as defined herein, taking the following form: binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-linker-binding domain 3 (VH / VL-peptide linker-VH / VL).
[0067] As described herein, the polypeptide constructs of the present invention preferably include a binding domain that binds to CD3 on the surface of T cells. "CD3" (differentiation cluster 3) is a T cell coreceptor composed of four chains. In mammals, the CD3 protein complex contains a CD3γ (gamma) chain, a CD3δ (delta) chain, and two CD3ε (epsilon) chains. These four chains associate with the T cell receptor (TCR) and the so-called ζ (zeta) chain to form the "T cell receptor complex," which generates an activation signal in T lymphocytes. The CD3γ (gamma), CD3δ (delta), and CD3ε (epsilon) chains are highly related cell surface proteins of the immunoglobulin superfamily, each containing a single extracellular immunoglobulin domain. The intracellular tail of the CD3 molecule contains a single conserved motif known as the immunoreceptor tyrosine activation motif (ITAM), which is essential for the signaling ability of the TCR. The CD3 epsilon molecule is a polypeptide encoded by the CD3 epsilon gene located on human chromosome 11. In the context of this invention, CD3 is understood as a protein complex and T cell coreceptor involved in the activation of both cytotoxic T cells (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). CD3 is typically composed of four distinct chains. In mammals in particular, this complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T cell receptor (TCR) and the ζ chain (zeta chain) to produce an activation signal in T lymphocytes. The TCR, ζ chain, and CD3 molecule together constitute the TCR complex.
[0068] Lysis of target cells redirected via T cell recruitment by constructs that bind CD3 on T cells and target proteins on target cells generally involves cytolytic synapse formation and delivery of perforins and granzymes. The associated T cells possess a range of target cell lytic capabilities and are unaffected by immune escape mechanisms that prevent peptide antigen processing and presentation or clonal T cell differentiation; see, for example, International Publication No. 2007 / 042261.
[0069] Cytotoxicity mediated by a given tumor antigen × CD3 construct can be measured in various ways. The "maximum half-volume effective concentration" (EC50) is commonly used as a measure of the potency of biologically active molecules, such as the constructs of the present invention. This can be expressed in molar units. In this case, when measuring cytotoxicity, the EC50 value refers to the concentration of the construct that induces an intermediate cytotoxic response (lysation of target cells) between baseline and maximum. Effector cells in a cytotoxicity assay may be, for example, stimulated enriched (human) CD8-positive T cells or unstimulated (human) peripheral blood mononuclear cells (PBMCs). Typically, the EC50 value can be expected to be lower when stimulated / enriched CD8+ T cells are used as effector cells compared to unstimulated PBMCs. If the target cells are of macaque origin or have been transfused with a given macaque tumor antigen, the effector cells should also be of macaque origin, such as a macaque T cell line, e.g., 4119LnPx. The target cells should express the tumor antigen on their cell surface. The target cells may be cell lines (such as CHOs) that have been stably or transiently transferred with the tumor antigen. Alternatively, the target cells may be tumor antigen-positive naturally expressing cell lines, such as human cancer cells. Typically, the EC50 value is expected to be lower when using target cells that express higher levels of the tumor antigen on their cell surface compared to target cells with lower target expression rates.
[0070] The effector-to-target cell (E:T) ratio in cytotoxic assays is typically around 10:1, but this ratio can also vary. The cytotoxic activity of tumor antigen × CD3 constructs can be measured in a 51-chromium release assay (e.g., using an incubation time of approximately 18 hours) or in a FACS-based cytotoxic assay (e.g., using an incubation time of approximately 48 hours). Modifications to the incubation time (cytotoxic response) are also possible. Other methods for measuring cytotoxicity are well known and include MTT or MTS assays, ATP-based assays including bioluminescence assays, sulforhodamine B (SRB) assays, WST assays, clonality assays, and ECIS technology.
[0071] According to one embodiment, the cytotoxic activity mediated by the tumor antigen × CD3 construct of the present invention is measured in a cell-based cytotoxicity assay. This can also be measured in a 51-chromium release assay. The EC50 values of the construct of the present invention are assumed to be ≤300pM, ≤280pM, ≤260pM, ≤250pM, ≤240pM, ≤220pM, ≤200pM, ≤180pM, ≤160pM, ≤150pM, ≤140pM, ≤120pM, ≤100pM, ≤90pM, ≤80pM, ≤70pM, ≤60pM, ≤50pM, ≤40pM, ≤30pM, ≤20pM, ≤15pM, ≤10pM, or ≤5pM.
[0072] The given EC50 values described above can be measured under different conditions in different assays. For example, when human PBMCs are used as effector cells and tumor antigen-transplanted cells such as CHO cells are used as target cells, the EC50 values of the tumor antigen × CD3 construct are expected to be ≤500pM, ≤400pM, ≤300pM, ≤280pM, ≤260pM, ≤250pM, ≤240pM, ≤220pM, ≤200pM, ≤180pM, ≤160pM, ≤150pM, ≤140pM, ≤120pM, ≤100pM, ≤90pM, ≤80pM, ≤70pM, ≤60pM, ≤50pM, ≤40pM, ≤30pM, ≤20pM, ≤15pM, ≤10pM, or ≤5pM. When human PBMCs are used as effector cells, and the target cells are CLDN6-positive cell lines such as [list of cell lines], the EC50 values of the CLDN6×CD3 construct are expected to be ≤300pM, ≤280pM, ≤260pM, ≤250pM, ≤240pM, ≤220pM, ≤200pM, ≤180pM, ≤160pM, ≤150pM, ≤140pM, ≤120pM, ≤100pM, ≤90pM, ≤80pM, ≤70pM, ≤60pM, ≤50pM, ≤40pM, ≤30pM, ≤20pM, ≤15pM, ≤10pM, or ≤5pM.
[0073] According to one embodiment, the tumor antigen × CD3 polypeptide / polypeptide construct of the present invention does not induce / intervene in lysis, or essentially does not induce / intervene in the lysis of cells that do not express the given tumor antigen on the surface of cells such as CHO cells (tumor antigen-negative cells). The terms “does not induce lysis,” “essentially does not induce lysis,” “does not intervene in lysis,” or “essentially does not intervene in lysis” mean that the construct of the present invention does not induce or intervene in the lysis of more than 30%, preferably 20% or less, more preferably 10% or less, particularly preferably 9%, 8%, 7%, 6%, or 5% or less of tumor antigen-negative cells, thereby setting the lysis of tumor antigen-expressing target cells (cells transformed with or transplanted with the tumor antigen, or naturally expressing cell lines such as human cancer lines) to 100%. This typically applies to construct concentrations up to 500 nM. Cell lysis measurement is a routine technique. Furthermore, this specification provides specific instructions for methods of measuring cell lysis.
[0074] The difference in cytotoxic activity between the monomeric and dimeric isoforms of individual tumor antigen × CD3 polypeptide / polypeptide constructs is referred to as the "potency gap." This potency gap can be calculated, for example, as the ratio between the EC50 value of the monomeric form of the molecule and the EC50 value of the dimeric form. One method for determining this gap is to perform an 18-hour 51-chromium release assay or a 48-hour FACS-based cytotoxicity assay using the monomeric and dimeric forms of the purified construct, as described later. Effector cells are stimulated enriched human CD8+ T cells or unstimulated human PBMCs. Target cells are CHO cells transplanted with human tumor antigens. The effector-to-target cell (E:T) ratio is 10:1. The potency gap of the tumor antigen × CD3 construct of the present invention is preferably ≤5, more preferably ≤4, even more preferably ≤3, even more preferably ≤2, and most preferably ≤1.
[0075] The binding domain of the polypeptide construct of the present invention is preferably cross-species specific to members of the order Mammalia, such as macaques. According to one embodiment, in addition to binding to human tumor antigens, further binding domains would also bind to the tumor antigens of primates, including (but not limited to) New World primates (such as marmosets (Callithrix jacchus), cotton-top tamarins (Saguinus Oedipus), or squirrel monkeys (Saimiri sciureus)), Old World primates (such as baboons and macaques), gibbons, orangutans, and non-human Hominidae. The domain of the present invention that binds to human CD3 on the surface of T cells is expected to bind to at least macaque CD3. A preferred macaque is the cynomolgus macaque (Macaca fascicularis). The rhesus macaque (Macaca mulatta) is also expected. The polypeptide or polypeptide construct of the present invention comprises a domain that binds to human CD3 epsilon and at least macaque CD3 on the surface of T cells.
[0076] In one embodiment, the affinity gap of the construct according to the present invention for binding human CD3 to macaque CD3 (as determined, for example, by BiaCore or scatchard analysis) [KD ma CD3:KD hu CD3] is 0.01 to 100, preferably 0.1 to 10, more preferably 0.2 to 5, more preferably 0.3 to 4, even more preferably 0.5 to 3 or 0.5 to 2.5, and most preferably 0.5 to 1.
[0077] As previously detailed herein, the binding domain of the polypeptide or polypeptide construct of the present invention binds to human CD3 epsilon (or human CD3 epsilon on the surface of T cells), preferably to CD3 epsilon of marmoset (Callithrix jacchus) or squirrel monkey (Saimiri sciureus). More specifically, the domain binds to the extracellular epitope of human CD3 epsilon. It is also conceivable that the domain binds to the extracellular epitope of human and the macaque CD3 epsilon chain. The extracellular epitope of CD3 epsilon is contained within amino acid residues 1-27 of the extracellular domain of human CD3 epsilon (see amino acid residues 1-27 of SEQ ID NOs. 847 and 848). More specifically, the epitope contains at least the amino acid sequence Gln-Asp-Gly-Asn-Glu. The marmoset (Callithrix jacchus) is a New World primate belonging to the family Callitrichidae, while the squirrel monkey (Saimiri sciureus) is a New World primate belonging to the family Cebidae. Binding agents with these properties are described in detail in International Publication No. 2008 / 119567.
[0078] Antibodies or bispecific constructs against (human) CD3, or selectively and preferably specifically against CD3 epsilon, are known in the Art, and their CDR, VH, and VL sequences can serve as the basis for the binding domain of the polypeptide constructs of the present invention. For example, Kung et al. reported in 1979 the development of OKT3 (Ortho Kung T3), the first mAb to recognize CD3 (specifically, the epsilon chain of CD3) on human T cells. OKT3 (muromonab) was the first mouse-derived monoclonal antibody to become available for therapeutic use in humans. More recent anti-CD3 monoclonal antibodies include otelixizumab (TRX4), teplizumab (MGA031), horalumab, and bicilizumab, all of which target the epsilon chain of CD3. Bispecific constructs targeting (cancer) targets and CD3 have also been developed and clinically tested, and their CD3-binding domains (CDR, VH, VL) may serve as the basis for the second binding domain of the constructs of the present invention. Examples, but not limited to, include blinatumomab, solitomab (MT110, AMG110), catumakisomab, duvortuxizumab, erzumakisomab, mosnetuzumab, FBTA05 (Bi20, TPBs05), CEA-TCB (RG7802, RO6958688), AFM11, and MGD006 (S80880). Other examples of CD3-binding domains are disclosed, for example, in U.S. Patent No. 7,994,289B2, U.S. Patent No. 7,728,114B2, U.S. Patent No. 7,381,803B1, and U.S. Patent No. 6,706,265B1.
[0079] The following table lists preferred combinations of CDR-L1 to L3 sequences in the VL region and CDR-H1 to H3 sequences in the VH region of the CD3 binding domain.
[0080] [Table 1]
[0081] Preferably, one of the CDR-L1 to L3 combinations listed above is combined with one of the CDR-H1 to H3 combinations listed above as the extracellular binding domain portion of the human CD3ε chain. In other words, the VL region consists of CDR-L1, CDR-L2, and CDR-L3 sequences in this order. GSSTGAVTSGYYPN, GTKFLAP, ALWYSNRWV; RSSTGAVTSGYYPN, ATDMRPS, ALWYSNRWV; GSSTGAVTSGNYPN, GTKFLAP, VLWYSNRWV; ASSTGAVTSGNYPN, GTKFLVP, TLWYSNRWV; or RSSTGAVTTSNYAN, GTNKRAP, ALWYSNLWV, or any of these, and The VL region consists of the CDR-H1, CDR-H2, and CDR-H3 sequences, in that order. IYAMN, RIRSKYNNYATYYADSVKS, HGNFGNSYVSFFAY; KYAMN, RIRSKYNNYATYYADSVKD, HGNFGNSYISYWAY; SYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYLSFWAY; RYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYLSYFAY; VYAMN, RIRSKYNNYATYYADSVKK, HGNFGNSYLSWWAY; KYAMN, RIRSKYNNYATYYADSVKS, HGNFGNSYTSYYAY; GYAMN,RIRSKYNNYATYYADSVKE,HRNFGNSYLSWFAY; VYAMN, RIRSKYNNYATYYADSVKK, HGNFGNSYISWWAY; SYAMN, RIRSKYNNYATYYADSVKG, HGNFGNSYVSWWAY; KYAIN, RIRSKYNNYATYYADQVKD, HANFGNSYISYWAY; or It includes or consists of TYAMN, RIRSKYNNYATYYADSVKD, and HGNFGNSYVSWFAY.
[0082] According to the present invention, preferred combinations of CDR sequences of the VH and VL regions listed in the order CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3 are sequence numbers 82-87, 88-93; 94-99, 100-105, 106-111, 112-117, 118-123, 124- As defined in sections 129, 130-135, 136-141, 142-147, 148-153, 154-159, 160-165, 166-171, 172-177, 178-183, 184-189, 190-195, 196-201, 202-207, 208-213, 214-219, and 220-225.
[0083] Most preferably, the VL region contains the same combination of CDRs as shown in sequence numbers 106-111, 112-117; 118-123, 124-129, 178-183, 184-189, 190-195, 196-201, 202-207, 208-213, 214-219, and 220-225, where the sequences CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 are listed in that order. Preferably, the orientation of the CDRs is from VH to VL, i.e., the orientation of the variable region is from VH to VL, from the N-terminus to the C-terminus.
[0084] Preferred combinations of VH and VL region sequences of the CD3-binding domain contained in the polypeptide or polypeptide construct of the present invention are found in the sequence numbers (listed in the order of VH+VL sequences): 550+551, 552+553, 554+555, 556+557, 558+559, 560+561, 562+563, 564+565, 566+567, 568+569, 570+571, 572+573, 574+575, 576+577, 578+579, 580+581, 582+583, 584+585, 586+587, 588+589, 590+591, 592+593, 594+595, 596+597. Preferred CD3 binding domains are selected from SEQ ID NOs: 558+559, 560+561, 562+563, 564+565, 582+583, 584+585, 586+587, 588+589, 590+591, 592+593, 594+595, and 596+597.
[0085] In another preferred embodiment, the linker linking the binding domains, the polypeptide or polypeptide construct of the present invention, comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20. As outlined above in this specification, it is advantageous that two or more linkers in the polypeptide or polypeptide construct of the present invention are as defined above in this specification. For this reason, it is preferable that the linker linking the binding domains is also as defined above in this specification. The linker linking the binding domains and the linker linking the VH variable region and VL variable region within the binding domain are most preferably S(G4Q)n or (G4Q)n linkers as defined herein, wherein the linker is a linker containing serine instead of glutamine, i.e., an S(G4S)n linker or (G4S)n linker.
[0086] Preferably, the linker that links the binding domains of the polypeptide or polypeptide construct of the present invention is S(G4X)n, where n is 1 and X is Q. In other words, preferably the linker that links all of the binding domains of the polypeptide or polypeptide construct of the present invention is S(G4Q) (SEQ ID NO: 34).
[0087] In a more preferred embodiment, the polypeptide or polypeptide construct of the present invention comprises a half-life extension domain. The polypeptide construct of the present invention may also have further functions in addition to its function of binding to the target antigen (preferably when the polypeptide or polypeptide construct comprises a CD3 binding domain and at least one further binding domain that binds to a tumor antigen). In this form, the construct may be triplicate or multifunctional by providing further functions such as a means or domain that targets target cells through tumor antigen binding, mediates cytotoxic T cell activity through CD3 binding and enhances or extends serum half-life, a fully functional or modified Fc constant domain that mediates cytotoxicity through the recruitment of effector cells, a therapeutic agent such as a label (fluorescence, etc.), a toxin, or a radionuclide.
[0088] Examples of means or domains for extending the serum half-life of polypeptide / polypeptide constructs of the present invention include peptide, protein, or protein domains that fused to or otherwise attached to the polypeptide / polypeptide construct. The group of peptide, protein, or protein domains includes peptides that bind to other proteins having a favorable pharmacokinetic profile in the human body, such as serum albumin (see International Publication No. 2009 / 127691). An alternative concept for such half-life-extending peptides includes peptides that bind to the neonatal Fc receptor (FcRn, see International Publication No. 2007 / 098420), which can also be used in constructs of the present invention. The concept of attaching larger domains or complete proteins to proteins includes the fusion of human serum albumin, human serum albumin (see International Publication Nos. 2011 / 051489, 2012 / 059486, 2012 / 150319, 2013 / 135896, 2014 / 072481, and 2013 / 075066) or variants or mutants of its domain, as well as the fusion of immunoglobulin constant regions (Fc domains) and their variants. Such variants of the Fc domain are called Fc-based domains and may be optimized / modified, for example, to enable desired pairing of dimers or multimers, to disable Fc receptor binding (e.g., to evade ADCC or CDC), or for other reasons. A further concept known in the art for extending the half-life of substances or molecules in the human body is the pegylation of those molecules (such as the constructs of the present invention).
[0089] In one embodiment, the polypeptide / polypeptide construct according to the present invention is linked (e.g., via a peptide bond) to a fusion partner (e.g., a protein, polypeptide, or peptide) to extend the serum half-life of the construct. These fusion partners can be selected from human serum albumin ("HSA" or "HALB") and its sequence variants, peptides that bind to HSA, peptides that bind to FcRn ("FcRn BP"), or constructs containing an (antibody-derived) Fc region. Generally, the fusion partner can be linked either directly (e.g., via a peptide bond) to the N-terminus or C-terminus of the construct according to the present invention, or via a peptide linker such as (GGGGQ)n, (GGGGS)n, or GGGG (wherein "n" is an integer of 2 or more, e.g., 2, 3, or 4). Specific suitable peptide linkers are discussed above.
[0090] Preferably, the half-life extension domain (HLE domain) comprises or consists of two polypeptide monomers, each having a hinge, a CH2 domain, and a CH3 domain, wherein the two polypeptide monomers are fused to each other via a peptide linker comprising hinge-CH2-CH3-peptide linker-hinge-CH2-CH3 in an amino-to-carboxyl sequence. The preferred polypeptide monomer of the HLE domain comprises or consists of the sequence of SEQ ID NO: 78 or 79, and the sequence of the entire HLE domain is defined by SEQ ID NO: 849. The sequence of the HLE domain monomer is preferably modified by deletion of the "DKTHT" sequence motif at the N-terminus and / or by substitution of amino acid D at position 55 of SEQ ID NO: 78 or 79 with amino acid E. Preferably, all modifications, namely the deletion of the DKTHT motif and the substitution at position 55, are present in each HLE domain monomer fused to each other via a peptide linker. The peptide linker is preferably (GGGGQ)n or (GGGGS)n (wherein "n" is an integer of 2 or more, e.g., 2, 3, 4, 5, or 6, preferably 6). A particularly preferred linker is (G4Q)6. Each of the latter features / modifications contributes to a further reduction in the clipping rate. Therefore, the combination of (G4Q)6 as a linker to fuse the HLE domain monomer modified by the deletion of the "DKTHT" sequence motif at the N-terminus and by the substitution of amino acid D at position 55 of SEQ ID NO: 78 or 79 with amino acid E is a preferred embodiment of the present invention (as in SEQ ID NOs: 80 and 81). The corresponding preferred HLE domain includes or consists of the sequence defined in SEQ ID NO: 850.
[0091] According to the present invention, the polypeptide or polypeptide construct comprises a binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-HLE domain in an order from amino to carboxyl. The HLE domain is preferably linked to the polypeptide or polypeptide construct of the present invention via a peptide linker such as (GGGGQ)n, (GGGGS)n, or GGGG (wherein "n" is an integer of 2 or more, for example, 2, 3, or 4). More preferably, the linker is GGGG.
[0092] Furthermore, according to the present invention, the polypeptide or polypeptide construct includes a binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-linker-binding domain 3 (VH / VL-peptide linker-VH / VL)-HLE domain in the order from amino to carboxyl.
[0093] Furthermore, according to the present invention, the polypeptide or polypeptide construct comprises, in the order from amino to carboxyl, binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-linker-HLE domain-linker-binding domain 3 (VH / VL-peptide linker-VH / VL)-linker-binding domain 4 (VH / VL-peptide linker-VH / VL), where binding domain 1 binds to a first cell surface antigen, binding domains 2 and 3 bind to CD3, and binding domain 4 binds to a second cell surface antigen. It is even more preferable that the peptide linker in the binding domain is (G4Q)3, the peptide linker in the HLE domain is (G4Q)6, the linker linking the binding domains is S(G4Q), and the linker linking the HLE domain to the binding domain is a G4 linker. It is even more preferable that the HLE domain contains or consists of the sequence of SEQ ID NO: 850. The binding domain that binds to CD3 contains or consists of VH and VL sequences as defined by SEQ ID NOs: 582 and 583, 584 and 585, 586 and 587, or 588 and 589.
[0094] According to the present invention, the linker that ligates the HLE domain to the binding domain is the G4 linker in the polypeptide or polypeptide construct of the present invention.
[0095] Accordingly, in accordance with the foregoing, the polypeptide or polypeptide construct according to the present invention comprises a single-chain polypeptide having at least one binding domain that binds to CD3, at least one binding domain that binds to a cell surface antigen, preferably a tumor antigen, and optionally an HLE domain, wherein the polypeptide has the following properties from the N-terminus to the C-terminus: a) VL (containing cell surface antigen-binding domain / part of paratope)-(G4Q)3-VH (containing cell surface antigen-binding domain / part of paratope)-peptide linker(SG4Q)-VH (containing CD3 epsilon-binding domain / part of paratope)-(G4Q)3-VL (containing CD3 epsilon-binding domain / part of paratope), b) VH(containing cell surface antigen-binding domain / part of paratope)-(G4Q)3-VL(containing cell surface antigen-binding domain / part of paratope)-peptide linker(SG4Q)-VH(containing CD3 epsilon-binding domain / part of paratope)-(G4Q)3-VL(containing CD3 epsilon-binding domain / part of paratope); c) VL (containing part of the cell surface antigen-binding domain / paratope)-(G4Q)3-VH (containing part of the cell surface antigen-binding domain / paratope)-peptide linker(SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker(G4)-Fc monomer (part of the preferred HLE domain described herein)-(G4Q)6-Fc monomer (complementary part of the preferred HLE domain described herein), d) VH (containing part of the cell surface antigen-binding domain / paratope)-(G4Q)3-VL (containing part of the cell surface antigen-binding domain / paratope)-peptide linker (SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4Q)6-Fc monomer (part of the HLE domain), e) VH (containing part of the first cell surface antigen-binding domain / paratope)-((G4Q)3-VL (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4Q)-VL (containing part of the second cell surface antigen-binding domain / paratope)-(G4Q)3-VH (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4Q)6 or-Fc monomer (part of the HLE domain), f) VH (containing part of the first cell surface antigen-binding domain / paratope)-(G4Q)3-VL (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker (SG4Q)-VH (containing part of the second cell surface antigen-binding domain / paratope)-(G4Q)3-VL (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker (SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4Q)6 or-Fc monomer (part of the HLE domain), g) VL (containing part of the first cell surface antigen-binding domain / paratope)-(G4Q)3-VH (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker(SG4Q)-VL (containing part of the second cell surface antigen-binding domain / paratope)-(G4Q)3-VH (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker(SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker(G4)-Fc monomer (part of the HLE domain)-(G4Q)6 or-Fc monomer (part of the HLE domain), h) VL (containing part of the first cell surface antigen-binding domain / paratope)-(G4Q)3-VH (containing part of the first cell surface antigen-binding domain / paratope)-peptide linker(SG4Q)-VH (containing part of the second cell surface antigen-binding domain / paratope)-(G4Q)3-VL (containing part of the second cell surface antigen-binding domain / paratope)-peptide linker(SG4Q)-VH (containing part of the CD3 epsilon-binding domain / paratope)-(G4Q)3-VL (containing part of the CD3 epsilon-binding domain / paratope)-peptide linker(G4)-Fc monomer (part of the HLE domain)-(G4Q)6 or-Fc monomer (part of the HLE domain), or i) Binding domain 1 ((VL (including part of the first cell surface antigen binding domain / paratope)-(G4Q)3-VH (including part of the first cell surface antigen binding domain / paratope)) or (VH (including part of the first cell surface antigen binding domain / paratope)-(G4Q)3-VL (including part of the first cell surface antigen binding domain / paratope)))-peptide linker (G4Q)-CD3 binding domain 1 (VH (including part of the first CD3 epsilon binding domain / paratope)-(G4Q)3-VL (including part of the first CD3 epsilon binding domain / paratope))-peptide linker (G4)-Fc monomer (part of the HLE domain)-(G4Q)6- It comprises or consists of an Fc monomer (part of the HLE domain) - peptide linker (G4) - binding domain 2 ((VL (including part of the second cell surface antigen binding domain / paratope)-(G4Q)3-VH (including part of the first cell surface antigen binding domain / paratope)) or (VH (including part of the second cell surface antigen binding domain / paratope)-(G4Q)3-VL (including part of the second cell surface antigen binding domain / paratope))) - peptide linker (G4Q) - CD3 binding domain 2 (VH (including part of the second CD3 epsilon binding domain / paratope)-(G4Q)3-VL (including part of the second CD3 epsilon binding domain / paratope)).
[0096] As is clear from the above, the orientation of the sequences of the VH and VL regions of the cell surface antigen binding domain can be VH-VL or VL-VH. Preferably, the cell surface antigen is a tumor antigen, which will be detailed later herein. The HLE domain sequence, which consists of the Fc monomer and linking linker, which will be detailed herein, is preferably selected from the sequences defined by SEQ ID NOs: 80, 81, and 72, respectively, with the preferred HLE domain sequence being as defined by SEQ ID NO: 850. The two CD3-binding domains of the polypeptide construct in item i) are preferably the same CD3-binding domain, for example, preferably the CD3-binding domain having VH region sequences and VL region sequences of SEQ ID NOs. 582+583, 584+585, 586+587, and 588+589, preferably the same CD3-binding domain as defined in SEQ ID NOs. 722-725, more preferably the same CD3-binding domain, such as the CD3-binding domain where 724 and 725 have a (G4Q)3 linker linking the VH region and the VL region. The peptide linker (SG4Q) is preferred at the indicated position but can be replaced by a (G4Q) linker or an SG4S linker.
[0097] In a more preferred embodiment, where the VH region in the cell surface antigen, preferably tumor antigen-binding domain of the polypeptide or polypeptide construct of the present invention precedes the VL region, the amino acid "EI" is preferably present prior to the VL region and before the linker that ligates VH to the VL region, as a further means of reducing the clipping rate of the polypeptide or polypeptide construct of the present invention. The sequence listing includes the corresponding binding domain alone or as part of a longer polypeptide or polypeptide construct of the present invention.
[0098] Covalent modifications of polypeptides / polypeptide constructs are also within the scope of the present invention, generally occurring post-translation, but not necessarily. For example, several types of covalent modifications of a construct are introduced intramolecularly by reacting specific amino acid residues of the construct with organic derivatization factors that can react with selected side chains or N-terminal or C-terminal residues. Derivatization with bifunctional factors is useful for crosslinking the constructs of the present invention to water-insoluble support matrices or surfaces for use in various ways. Glutaminyl and asparaginyl residues are often deamidated to their corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under weakly acidic conditions. Any form of these residues falls within the scope of the present invention. Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of ceryl or threonyl residues, methylation of α-amino groups of lysine, arginine, and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, 1983, pp. 79-86), acetylation of the N-terminal amine, and amidation of any of the C-terminal carboxyl groups.
[0099] Another type of covalent modification of constructs that falls within the scope of the present invention involves altering the glycosylation pattern of a protein. As is known in the art, the glycosylation pattern may depend on the sequence of the protein (e.g., the presence or absence of certain glycosylated amino acid residues, which will be discussed later) or on both the host cell or organism in which the protein is produced. Specific expression systems will be discussed later. Polypeptide glycosylation is typically either N-linked or O-linked. N-linking refers to the binding of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine (wherein X is any amino acid other than proline) are recognition sequences for enzymatic binding of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the binding of one of the sugars, N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[0100] The addition of glycosylation sites to a construct is conveniently achieved by altering the amino acid sequence (for N-linked glycosylation sites) to contain one or more of the aforementioned tripeptide sequences. The alteration can also be carried out by the addition or substitution of one or more serine or threonine residues to the starting sequence (for O-linked glycosylation sites). For ease of use, the amino acid sequence of a construct can be altered through DNA-level changes, particularly by mutating the polypeptide-encoding DNA with pre-selected bases to produce codons that will be translated into the desired amino acids.
[0101] Another means of increasing the number of carbohydrate moieties on a construct is by chemical or enzymatic coupling of glycosides to proteins. These procedures are advantageous in that they do not require the production of proteins in host cells that have glycosylation ability for N-linked and O-linked glycosylation. Depending on the coupling method used, sugars can be coupled to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) amide groups of glutamine. These methods are described in International Publication No. 87 / 05330 and in Aplin and Wriston, 1981, CRC Crit. Rev. Biochem., pp. 259-306.
[0102] The removal of carbohydrate chains present on the starting construct can be achieved chemically or enzymatically. Chemical deglycosylation requires exposure of the protein to the compound trifluoromethanesulfonic acid or an equivalent compound. This process results in the cleavage of almost all sugars except the linked sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., 1987, Arch. Biochem. Biophys. 259:52 and Edge et al., 1981, Anal. Biochem. 118:131. Enzymatic cleavage of sugar chains on polypeptides can be achieved using various endoglycosidases and exoglycosidases as described by Thotakura et al., 1987, Meth. Enzymol. 138:350. Glycosylation at potential glycosylation sites can be prevented by using the compound tunicamycin, as described by Duskin et al., 1982, J. Biol. Chem. 257:3105. Tunicamycin blocks the formation of protein-N-glycosidic bonds.
[0103] Other modifications of the construct are also contemplated herein. For example, another type of covalent modification of the construct involves linking the construct to various non-proteinaceous polymers containing a polyol in a manner shown in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. In addition, as is known in the art, amino acid substitutions may be made at various positions within the construct to facilitate the addition of polymers such as polyethylene glycol (PEG).
[0104] In some embodiments, the covalent modification of the construct of the invention includes the addition of one or more labels. To reduce potential steric hindrance, the label group may be linked to the construct via spacer arms of various lengths. Various methods for labeling proteins are known in the art and can be used in practicing the present invention. The term "label" or "label group" refers to any detectable label. In general, labels are classified into various classes depending on the assay in which they will be detected, and examples include, but are not limited to, the following. a) Radioisotopes or radionuclides (e.g., 3 H, 14 C, 15 N, 35 S, 89 Zr, 90 Y, 99 Tc, 111 In, 125 I, 131 I) and other isotope labels that can be radioactive or heavy isotopes b) Magnetic labels (e.g., magnetic particles) c) Redox-active moieties d) Optical dyes such as fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), chemiluminescent groups, and phosphors that can be either "small molecule" phosphors or proteinaceous phosphors (including, but not limited to, chromophores, phosphors, and fluorophores) e) Enzyme groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase) f) Biotinylation group g) A predetermined polypeptide epitope recognized by a secondary reporter (e.g., leucine zipper pair sequence, binding site for secondary antibody, metal-binding domain, epitope tag, etc.).
[0105] "Fluorescent labeling" refers to any molecule that can be detected through its inherent fluorescent properties. Suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malasite green, stilbene, Lucifer yellow, Cascade Blue J, Texas red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and R-phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, rhodamine, and Texas This includes, but is not limited to, Red (Pierce, Rockford, IL), Cy5, Cy5.5, and Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes, including phosphors, are described in Richard P. Haugland's Molecular Probes Handbook.
[0106] Suitable protein-based fluorescent labels include green fluorescent protein, e.g., GFP from Renilla, Ptilosarcus, or Aequorea species (Chalfie et al., 1994, Science 263:802-805), EGFP (Clontech Laboratories, Inc., Genbank® accession number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc., 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H 1J9, Stauber, 1998, Biotechniques 24:462-471, Heim et al., 1996, Curr. Biol. 6:178-182), enhanced yellow fluorescent protein (EYFP, Clontech Laboratories, Inc.), and luciferase (Ichiki et al. al., 1993, J.Immunol. 150:5408-5417), β-galactosidase (Nolan et al.) al., 1988, Proc. Natl. Acad. Sci. USA 85:2603-2607), and Renilla (International Publication No. 92 / 15673, International Publication No. 95 / 07463, International Publication No. 98 / 14605, International Publication No. 98 / 26277, International Publication No. 99 / 49019, U.S. Patent Nos. 5,292,658; 5,418,155; 5,683,888; 5,741,668; 5,777,079; 5,804,387; 5,874,304; 5,876,995; 5,925,558) are also cited, but are not limited to these.
[0107] Leucine zipper domains are peptides that promote the oligomerization of the proteins in which they are found. Leucine zippers were originally discovered in various different proteins and have since been identified in several DNA-binding proteins (Landschulz et al., 1988, Science 240:1759). Known leucine zippers include naturally occurring peptides and dimerizing or trimerizing derivatives. Examples of leucine zipper domains suitable for producing soluble oligomeric proteins are described in the PCT application's international publication 94 / 10308 brochure, and a leucine zipper derived from lung surfactant protein D (SPD) is described in Hoppe et al., 1994, FEBS Letters 344:191. The use of modified leucine zippers enabling stable trimerization of heterologous proteins fused to them is described in Fanslow et al., 1994, Semin.Immunol.6:267-78.
[0108] The polypeptide constructs of the present invention may also include additional domains that, for example, aid in the isolation of molecules or relate to the adapted pharmacokinetic properties of molecules. Domains that aid in the isolation of constructs may be selected from peptide motifs or secondary introduction portions that can be captured in an isolation method, such as an isolation column. Non-limiting embodiments of such additional domains include peptide motifs known as Myc-tags, HAT-tags, HA-tags, TAP-tags, GST-tags, chitin-binding domains (CBD-tags), maltose-binding protein (MBP-tags), Flag-tags, Strep-tags and their variants (e.g., StrepII-tags), and His-tags. All constructs disclosed herein that feature identified CDRs may include His-tag domains, which are generally known as consecutive His residues in the amino acid sequence of molecules, for example, repeats of five His residues or six His residues (hexa-histidine). The His tags may be located, for example, at the N-terminus or C-terminus of the construct. In one embodiment, a hexahistidine tag (HHHHHH) is linked to the C-terminus of the construct according to the present invention via a peptide bond. A histidine tag, particularly a 6×Hi tag, is preferred.
[0109] According to the present invention, if the polypeptide or polypeptide construct of the present invention includes a further binding domain, i.e., is at least bispecific, the cell surface antigen to which the target antigen-binding domain binds is preferably a tumor antigen. Preferably, the polypeptide or polypeptide construct of the present invention is a T cell engager. Therefore, it is preferable that the polypeptide or polypeptide construct of the present invention includes at least a CD3-binding domain and a tumor antigen-binding domain.
[0110] In preferred embodiments, the tumor antigens include BCMA (B cell maturation antigen), CD123 (interleukin-3 receptor alpha chain (IL-3R)), CD19 (B lymphocyte antigen CD19), CD20 (B lymphocyte antigen CD20), CD22 (differentiation cluster-22), CD33 (Siglec-3), CD70 (differentiation cluster 70), CDH19 (cadherin 19), CDH3 (cadherin 3), CLL1 (C-type lectin domain family 12 member A), and CS1 (CCND3 subset 1). The following are selected from the group consisting of ), CLDN6 (Claudin-6), CLDN18.2 (Claudin-18.2), DLL3 (Delta-like ligand 3), EGFRvIII (Epidermal growth factor receptor vIII), FLT3 (fms-like kinase 3), MAGEB2 (Melanoma-associated antigen B2), MART1 (Melanoma antigen 1 recognized by T cells), MSLN (Mesothelin), MUC17 (Mucin-17), PSMA (Prostate-specific membrane antigen), and STEAP1 (Metalloreductase STEAP1). These tumor antigens are well known in the art due to their expression on tumor cells.
[0111] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the BCMA binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a BCMA binding domain as the binding domain are defined in SEQ ID NOs: 238-243, 244-249, 602+603, 604+605, 732, 733, 784, and 794.
[0112] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CD123 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and the bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a CD123 binding domain as the binding domain are defined by SEQ ID NOs: 250-255, 256-261, 608+609, and 735.
[0113] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CD19 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and the bispecific single-chain molecular sequences of the polypeptide or polypeptide construct according to the present invention having a CD19 binding domain as the binding domain are defined by SEQ ID NOs: 268-273, 612+613, 737, and 797.
[0114] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CD33 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a CD33 binding domain as the binding domain are defined in SEQ ID NOs: 286-291, 298-303, 304-309, 618+619, 622+623, 624+625, 740, 742, 743, 786, and 799.
[0115] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CD70 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a CD70 binding domain as the binding domain are defined in SEQ ID NOs: 316-321, 628+629, 745, and 801.
[0116] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CDH19 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the CDH19 binding domain as the binding domain are defined in SEQ ID NOs: 328-333, 632+633, 747, and 803.
[0117] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CDH3 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a CDH3 binding domain as the binding domain are defined in SEQ ID NOs: 340-345, 346-351, 358-363, 642+643, 749, 750, 752, 805, 844, and 846.
[0118] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CLDN18.2 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the CLDN18.2 binding domain as the binding domain are defined in SEQ ID NOs: 370-375, 646+647, 754, and 812.
[0119] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CLL1 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the CLL1 binding domain as the binding domain are defined in SEQ ID NOs: 328-387, 650+651, 756, and 806.
[0120] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CLDN6 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the CLDN6 binding domain as the binding domain are defined in SEQ ID NOs: 394-399, 654+655, 758, and 810.
[0121] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the CS1 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a CS1 binding domain as the binding domain are defined in SEQ ID NOs: 412-417, 660+661, 761, 839, and 840.
[0122] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the DLL3 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and the bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the DLL3 binding domain as the binding domain are defined in SEQ ID NOs: 424-429, 664+665, 763, and 814.
[0123] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the EGFRvIII binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the EGFRvIII binding domain as the binding domain are defined in SEQ ID NOs: 436-441, 668+669, 765, and 789.
[0124] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the FLT3 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the FLT3 binding domain as the binding domain are defined in SEQ ID NOs: 448-453, 672+673, 767, 818, and 843.
[0125] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the MAGEB2 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the MAGEB2 binding domain as the binding domain are defined in SEQ ID NOs: 460-465, 472-477, 676+677, 680+681, 769, 771, 823, and 825.
[0126] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the MSLN-binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having an MSLN-binding domain as the binding domain are defined in SEQ ID NOs: 484-489, 490-495, 502-507, 684+685, 686+687, 690+691, 773, 774, 776, and 827.
[0127] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the MUC17 binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having the MUC17 binding domain as the binding domain are defined in SEQ ID NOs: 514-519, 694-695, 778, and 829.
[0128] Preferred CDR sequences and VH / VL region sequences, as well as combinations thereof, for the PSMA-binding domain as the binding domain of the polypeptide or polypeptide construct of the present invention, and bispecific single-chain molecular sequences of polypeptides or polypeptide constructs according to the present invention having a PSMA-binding domain as the binding domain are defined in SEQ ID NOs: 532-537, 538-543, 544-549, 700+701, 702+703, 781, 782, 783, 790, and 831.
[0129] The present invention also relates to a method for improving the stability of a polypeptide or polypeptide construct comprising a first target antigen-binding domain, wherein the first target antigen-binding domain comprises VH and VL variable regions linked by a peptide linker, the peptide linker comprises or consists of S(G4S)n and (G4S)n, where n is an integer selected from 1 to 20, and the method comprises the step of substituting the S(G4S)n or (G4S)n linker with a peptide linker, wherein the peptide linker comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from 1 to 20. In a preferred embodiment of the method of the present invention, the integer n is 1, 2, 3, 4, 5, or 6. According to the present invention, X in S(G4X)n or (G4X)n is preferably Q. Such a peptide linker is S(G4Q)n or (G4Q)n. In a preferred embodiment, the peptide linker is (G4X)n, where n is 3 and X is Q. Thus, the peptide linker has the form (G4Q)3. All preferred embodiments described above herein with respect to the polypeptides or polypeptide constructs of the present invention also apply to methods for improving stability. Such a method can be used to improve the stability of any of the polypeptides or polypeptide constructs listed herein, provided that the polypeptide or polypeptide construct comprises an S(G4S)n linker and a (G4S)n linker, which is then substituted with the peptide linker, where the peptide linker comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from integers 1 to 20 by the method of the present invention. More specifically, the present invention relates to methods for improving the stability of polypeptides or polypeptides of the following forms.Binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL); binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-HLE domain (amino to carboxyl order); binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-linker-binding domain 3 (VH / VL-peptide linker-VH / VL)-HLE domain (amino to carboxyl order), or binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-linker- The HLE domain-linker-binding domain 3(VH / VL-peptide linker-VH / VL)-linker-binding domain 4(VH / VL-peptide linker-VH / VL) (in order from amino to carboxyl), and the peptide linker, binding domain, or linker within the HLE domain (HLE domain as defined above herein) linking the VH region and the VL region includes or consists of S(G4S)n and (G4S)n, where n is an integer selected from 1 to 20, and the procedure includes substituting the S(G4S)n or (G4S)n linker with a peptide linker, where the peptide linker includes or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L, and M, and n is an integer selected from 1 to 20. In a preferred embodiment of the method of the present invention, the integer n is 1, 2, 3, 4, 5, or 6. According to the present invention, X in S(G4X)n or (G4X)n is preferably Q. Thus, the peptide linker is S(G4Q)n or (G4Q)n. Preferred linkers for each position in different forms of the polypeptide or polypeptide construct are described above herein with respect to the polypeptide or polypeptide construct of the present invention, which also applies to this embodiment.
[0130] As used herein, “improvement of stability” relates to a reduction in the clipping rate. For this reason, the method may also be called a method for reducing the clipping rate of a polypeptide or polypeptide construct comprising a first target antigen-binding domain, wherein the first target antigen-binding domain comprises VH and VL variable regions linked by a peptide linker, and the peptide linker comprises or consists of S(G4S)n and (G4S)n, where n is an integer selected from 1 to 20. Preferred methods for determining the clipping rate are described in the examples.
[0131] The present invention also relates to polynucleotides encoding polypeptides or polypeptide constructs of the present invention. A nucleic acid molecule is a biopolymer composed of nucleotides. A polynucleotide is a biopolymer composed of 13 or more nucleotide monomers covalently linked in a chain. DNA (e.g., cDNA) and RNA (e.g., mRNA) are examples of polynucleotide / nucleic acid molecules with different biological functions. A nucleotide is an organic molecule that functions as a monomer or subunit of a nucleic acid molecule such as DNA or RNA. The nucleic acid molecule or polynucleotide of the present invention may be double-stranded or single-stranded, linear or cyclic. The nucleic acid molecule or polynucleotide is envisioned to be contained in a vector. Furthermore, such a vector is envisioned to be contained in a host cell. The host cell can, for example, express a construct after transformation or translocation with the vector or polynucleotide / nucleic acid molecule of the present invention. For this purpose, the polynucleotide or nucleic acid molecule is operably linked to a control sequence.
[0132] The genetic code is a set of rules governing the translation of information encoded within genetic material (nucleic acids) into proteins. Biological decoding in living cells is achieved by ribosomes, which ligate amino acids in the order specified by mRNA, using tRNA molecules that carry amino acids and read three nucleotides from mRNA at once. This code defines how a sequence of three nucleotides, called a codon, specifies the next amino acid to be added during protein synthesis. With a few exceptions, a three-nucleotide codon in a nucleic acid sequence specifies one amino acid. Because most genes are encoded with the exact same code, this particular code is often referred to as the reference genetic code or standard genetic code.
[0133] Codon degeneracy is the redundancy of the genetic code, expressed as multiple combinations of 3-base pair codons that specify an amino acid. Degeneracy arises because there are far more codons than amino acids they can code for. Codons(s) coding for a single amino acid can differ in any of their three positions, but often this difference lies in the second or third position. For example, codons GAA and GAG both specify glutamic acid, exhibiting redundancy, but neither specifies any other amino acid and therefore exhibits no ambiguity. The genetic code of different organisms may be biased towards using one of several codons that code for the same amino acid more than others; i.e., the frequency of a single codon is higher than would be expected by chance. For example, leucine is specified by six distinct codons, some of which are rarely used. Codon usage tables detailing genomic codon usage frequencies for most organisms are available. In recombinant gene technology, this effect is often utilized by performing a technique called codon optimization, where polynucleotides are designed using codons preferred by each host cell (e.g., human, hamster-derived cells, Escherichia coli cells, or Saccharomyces cerevisiae cells) to increase protein expression, for example. Therefore, it is assumed that the polynucleotide / nucleic acid molecules of this disclosure are codon-optimized. Nevertheless, polynucleotide / nucleic acid molecules encoding the constructs of the present invention may be designed using any codon encoding a desired amino acid.
[0134] According to one embodiment, the polynucleotide / nucleic acid molecule of the present invention encoding the polypeptide construct of the present invention is in the form of a single molecule or two or more distinct molecules. If the construct of the present invention is a single-stranded construct, the polynucleotide / nucleic acid molecule encoding such a construct is most likely to also be in the form of a single molecule. However, it is also conceivable that different components of the polypeptide construct (e.g., different domains, such as a paratope-containing domain that binds to a cell surface antigen, a paratope-containing domain that binds to CD3, and / or an antibody constant domain) are located on separate polypeptide chains, in which case the polynucleotide / nucleic acid molecule is most likely to be in the form of two or more distinct molecules.
[0135] The same applies to vectors containing the polynucleotide / nucleic acid molecule of the present invention. If the construct of the present invention is a single-stranded construct, one vector may contain the polynucleotide encoding the construct in one location (as a single open reading frame, ORF). One vector may also contain two or more polynucleotide / nucleic acid molecules at separate locations (each having its own ORF), each of which encodes a different component of the construct of the present invention. A vector containing the polynucleotide / nucleic acid molecule of the present invention is envisioned to be in the form of a single vector or two or more separate vectors. In one embodiment, for the purpose of expressing the construct in a host cell, the host cell of the present invention should contain the polynucleotide / nucleic acid molecule encoding the construct, or a vector containing such polynucleotide / nucleic acid molecule as a whole, meaning that all components of the construct (whether encoded as a single molecule or at separate molecules / locations) assemble post-translation to form a biologically active construct of the present invention.
[0136] Furthermore, the present invention relates to vectors comprising the polynucleotide / nucleic acid molecule of the present invention. A vector is a nucleic acid molecule typically used as a vehicle for transferring (exogenous) genetic material into a cell in order to ensure the replication and / or expression of the genetic material. The term “vector” includes, but is not limited to, plasmids, viruses, cosmids, and artificial chromosomes. Some vectors are specifically designed for cloning (cloning vectors), while others are designed for protein expression (expression vectors). So-called transcription vectors are primarily used to amplify their inserts. DNA manipulation is typically performed on E. coli vectors, which contain elements necessary for their maintenance within E. coli. However, vectors may also have elements that allow them to be maintained in other organisms, such as yeast, plant, or mammalian cells; these vectors are called shuttle vectors. Insertion of a vector into a target or host cell is typically called transformation for bacterial cells and transduction for eukaryotic cells, while insertion of a viral vector is often called transduction.
[0137] Generally, a manipulated vector contains an origin of replication, multiple cloning sites, and selectable markers. The vector itself is typically a nucleotide sequence, usually a DNA sequence, containing an insert (transgene) and a larger sequence that acts as the vector's "backbone." The genetic code determines the polypeptide sequence of a given coding region, but other genomic regions can influence when and where these polypeptides are produced. Therefore, in addition to the transgene insert and backbone, modern vectors may include the following additional features: promoters, genetic markers, antibiotic resistance, reporter genes, targeting sequences, and protein purification tags. A vector called an expression vector (expression construct) is specifically for the expression of a transgene in target cells and generally contains a regulatory sequence.
[0138] The term "regulatory sequence" refers to a DNA sequence necessary for the expression of an operablely linked coding sequence in a particular host organism. Examples of regulatory sequences suitable for prokaryotes include promoters, sometimes operator sequences, and ribosome binding sites. Eukaryotic cells are known to utilize promoters, polyadenylation signals, Kozak sequences, and enhancers.
[0139] Nucleic acids are "operably linked" if they are placed in a functionally related position with another nucleic acid sequence. For example, a pre-sequence or secretion leader DNA is operably linked to the polypeptide DNA if this DNA is expressed as a preprotein involved in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if this affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if this ribosome binding site is positioned to facilitate translation. Generally, "operably linked" means that the linked nucleotide sequences are contiguous, and in the case of a secretion leader, contiguous and in the leading phase. Enhancers, however, do not need to be contiguous. Linking is achieved by ligation at a convenient restriction site. If such a site does not exist, synthetic oligonucleotide adapters or linkers are used, following conventional practice.
[0140] Transfusion is the process of intentionally introducing nucleic acid molecules or polynucleotides (including vectors) into target cells. This term is primarily used for non-viral methods in eukaryotic cells. Transfusion is often used to describe the viral transfer of nucleic acid molecules or polynucleotides. Transfusion in animal cells typically involves creating transient pores or "holes" in the cell membrane to allow material uptake. Transfusion can be performed using biological particles (e.g., viral transfusion, also called viral transfusion), chemical-based methods (e.g., using calcium phosphate, lipofection, Fugene, cationic polymers, nanoparticles, etc.), or physical treatments (e.g., electroporation, microinjection, gene gun, cell squeezing, magnetofection, hydrostatic pressure, impalefection, ultrasonic treatment, optical transfusion, heat shock).
[0141] The term "transformation" is used to describe the nonviral transfer of nucleic acid molecules or polynucleotides (including vectors) into non-animal eukaryotic cells, including bacteria and plant cells. Therefore, transformation is a genetic modification of a bacterial or non-animal eukaryotic cell resulting from the direct uptake from its periphery across the cell membrane and the subsequent integration of exogenous genetic material (nucleic acid molecules). Transformation can be achieved by artificial means. For transformation to occur, the cell or bacterium must be in a state of competence, which can occur as a time-limited response to environmental conditions such as starvation and cell density, and can also be artificially induced.
[0142] Furthermore, the present invention provides host cells transformed or transfused with the polynucleotide / nucleic acid molecule or vector of the present invention.
[0143] As used herein, the terms “host cell” or “recipient cell” are intended to include any individual cell or cell culture that may or may have been a recipient of a vector, exogenous nucleic acid molecule, and / or polynucleotide encoding a construct of the present invention, and / or a recipient of the construct itself. The introduction of individual materials into cells is carried out by transformation, translocation, and similar processes (see above). The term “host cell” is also intended to include single-cell passages or potential passages. Such passages may not be identical to the parent cell in practice (in morphological terms or in genomic DNA or total DNA supplementation factors) because certain modifications may occur in subsequent generations due to spontaneous, accidental, or intentional mutations, or due to environmental influences, but are still included within the scope of the term as used herein. Suitable host cells include prokaryotic or eukaryotic cells, and include, but are not limited to, bacteria (such as Escherichia coli), yeast cells, fungal cells, plant cells, and animal cells (e.g., insect cells, and mammalian cells, e.g., hamster, mouse, rat, macaque, or human).
[0144] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeasts are suitable cloning or expression hosts for the constructs of the present invention. Saccharomyces cerevisiae, or common baker's yeast, are among the most commonly used lower eukaryotic host microorganisms. However, several other genera, species, and strains are generally available and useful in the present invention, for example, Schizosaccharomyces pombe, K. lactis, K. fragilis (ATCC 12424), K. bulgaricus (ATCC 16045), K. wickeramii (ATCC 24178), K. waltii (ATCC 56500), and K. drosophilarum (ATCC 16045). Hosts of the genus Kluyveromyces, such as K. thermotolerans and K. marxianus (36906); yarrowia (European Patent No. 402226); Pichia pastoris (European Patent No. 183070); Candida; Trichoderma reesia (European Patent No. 244234); Neurospora crassa; Schwanniomyces occidentalis Hosts include the genus Schwanniomyces (such as Schwanniomyces occidentalis), as well as filamentous fungi such as Neurospora, Penicillium, Tolypocladium, and Aspergillus, such as A. nidulans and A. niger.
[0145] Host cells suitable for the expression of glycosylated constructs originate from multicellular organisms. Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains and variants, as well as corresponding acceptable insect host cells derived from hosts such as the armyworm (Spodoptera frugiperda), Aedes aegypti (Aedes aegypti), Aedes albopictus (Aedes albopictus), Drosophila melanogaster (Drosophila melanogaster), and silkworm (Bombyx mori), have been identified. Various virus strains for translocation (e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV) are publicly available, and such viruses may be used herein as viruses according to the present invention, and in particular may be used for translocation of armyworm (Spodoptera frugiperda) cells.
[0146] Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, Arabidopsis thaliana, and tobacco can also be used as hosts. Cloning and expression vectors useful for protein production in plant cell cultures are known to those skilled in the art. See, for example, Hiatt et al., Nature (1989) 342:76-78, Owen et al. (1992) Bio / Technology 10:790-794, Artsaenko et al. (1995) The Plant J 8:745-750, and Fecker et al. (1996) Plant Mol Biol 32:979-986.
[0147] However, the greatest interest has been in vertebrate cells, and the proliferation of vertebrate cells in culture (cell culture) has become a routine procedure. Examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 cell line (COS-7, ATCC CRL 1651, etc.), human embryonic kidney cell line (293 cells or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)), baby hamster kidney cells (BHK, ATCC CCL 10, etc.), Chinese hamster ovary cells / -DHFR (CHO, etc., Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), mouse Sertoli cells (TM4, etc., Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVI ATCC CCL 70, etc.); African green monkey kidney cells (VERO-76, ATCC These include CRL1587, human cervical cancer cells (HELA, ATCC CCL 2, etc.), canine kidney cells (MDCK, ATCC CCL 34, etc.), buffalo rat hepatocytes (BRL 3A, ATCC CRL 1442, etc.), human lung cells (W138, ATCC CCL 75, etc.), human hepatocytes (Hep G2, 1413 8065, etc.), mouse mammary gland tumors (MMT 060562, ATCC CCL-51, etc.), TRI cells (Mather et al., Annals NY Acad.Sci. (1982) 383:44-68), MRC 5 cells, FS4 cells, and human hepatocellular carcinoma cells (Hep G2, etc.).
[0148] In further embodiments, the present invention provides a method for producing a polypeptide or polypeptide construct of the present invention, comprising culturing host cells of the present invention under conditions that enable expression of the construct of the present invention, and recovering the produced construct from the culture.
[0149] As used herein, the term “culturing” refers to the in vitro maintenance, differentiation, growth, proliferation, and / or propagation of cells under appropriate conditions in a culture medium. Cells are grown and maintained in cell growth medium at appropriate temperatures and gas mixtures. Culture conditions vary widely for each cell type. Typical growth conditions are a temperature of approximately 37°C, a CO2 concentration of approximately 5%, and a humidity of approximately 95%. Recipes for growth media may differ, for example, in pH, the concentration of carbon sources (e.g., glucose), the nature and concentration of growth factors, and the presence of other nutrients (e.g., amino acids or vitamins). Growth factors used in supplemental media are often derived from animal blood serum (e.g., fetal bovine serum (FBS), calf serum (FCS), horse serum, and porcine serum). Cells can be grown either in suspension culture or as adherent cultures. There are also cell lines that can grow to higher densities than under adherent conditions because they have been modified to be viable in suspension culture.
[0150] The term “expression” includes any of the steps involved in the production of the construct of the present invention, including but not limited to transcription, post-transcriptional modification, translation, folding, post-translational modification, targeting to specific intracellular or extracellular locations, and secretion. The term “recover” refers to a series of processes intended to isolate a construct from a cell culture. The “recovery” or “purification” process can separate the protein and non-protein portions of a cell culture, ultimately separating the desired construct from all other polypeptides and proteins. The separation process typically utilizes differences in protein size, physicochemical properties, binding affinity, and biological activity. Preparative purification aims to produce relatively large quantities of purified protein for subsequent use, while analytical purification produces relatively small quantities of protein for various research or analytical purposes.
[0151] When recombinant technology is used, the construct can be produced intracellularly in the pericellular space or secreted directly into the culture medium. If the construct is produced intracellularly, the first step is to remove host cells or particulate fragments of the lysed fragment, for example, by centrifugation or ultrafiltration. The construct of the present invention can be produced in bacteria such as Escherichia coli (E. coli). After expression, the construct can be isolated from the bacterial cell paste in a soluble fraction and purified, for example, by affinity chromatography and / or size exclusion. Final purification can be carried out in the same way as the process for purifying constructs expressed in mammalian cells and secreted into the culture medium. Carter et al. (Biotechnology (NY) 1992 Feb;10(2):163-7) describe a procedure for isolating antibodies secreted into the pericellular space of Escherichia coli (E. coli).
[0152] When antibodies are secreted into the culture medium, the supernatant from such an expression system is generally first concentrated using a commercially available protein concentration filter, such as an ultrafiltration unit.
[0153] Constructions of the present invention prepared from host cells can be recovered or purified using, for example, hydroxyl apatite chromatography, gel electrophoresis, dialysis, and affinity chromatography. Other techniques for protein purification, such as fractionation with ion exchange columns, mixed-mode ion exchange, HIC, ethanol precipitation, size exclusion chromatography, reverse-phase HPLC, chromatography with silica, chromatography with heparin Sepharose, chromatography with anion or cation exchange resins (e.g., polyaspartate columns), immunoaffinity chromatography (e.g., protein A / G / L), chromatographic focusing, SDS-PAGE, ultracentrifugation, and ammonium sulfate precipitation, are also available depending on the construct to be recovered.
[0154] Any of the above processes may include protease inhibitors to inhibit protein degradation and antibiotics to prevent the growth of contaminants.
[0155] Furthermore, the present invention provides pharmaceutical compositions or formulations comprising polypeptides or polypeptide constructs of the present invention or polypeptides or polypeptide constructs produced by the methods of the present invention. As used herein, the term “pharmaceutical composition” refers to a composition suitable for administration to a patient, preferably a human patient. Particularly preferred pharmaceutical compositions of the present invention preferably contain one or more constructs of the present invention in therapeutically effective amounts. Preferably, the pharmaceutical composition further comprises a preferred formulation of one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives and / or adjuvants. The acceptable components of the composition are preferably nontoxic to the recipient at the doses and concentrations used. Pharmaceutical compositions of the present invention include, but are not limited to, liquid, freeze-dried, and lyophilized compositions.
[0156] The composition may contain a pharmaceutically acceptable carrier. Generally, as used herein, “pharmaceutically acceptable carrier” means all aqueous and non-aqueous solutions, sterile solutions, solvents, buffers, such as phosphate-buffered salt (PBS) solutions, water, suspensions, emulsions such as oil / water emulsions, various types of wetting agents, liposomes, dispersion media, and coatings suitable for the administration of a pharmacopoeia, particularly parenteral administration. The use of such media and activators in pharmaceutical compositions is well known in the art, and compositions containing such carriers can be formulated by well-known conventional methods.
[0157] Certain embodiments of the present invention provide a pharmaceutical composition comprising the construct of the present invention and one or more excipients, for example, those described exemplary in this section and elsewhere in this specification. In the present invention, excipients may be used for a variety of purposes (e.g., to adjust the physical, chemical, or biological properties of a formulation (e.g., viscosity adjustment)) and / or to improve efficacy and / or to stabilize such formulations and processes against degradation and deterioration caused by stress, for example, during manufacturing, shipping, storage, pre-preparation, administration and thereafter. Excipients are generally used at the lowest effective concentration.
[0158] In certain embodiments, the pharmaceutical composition may contain formulation materials for modifying, maintaining, or preserving specific properties of the composition, such as pH, molar osmotic pressure, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution rate or release rate, adsorption or osmosis (see Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Company). In such embodiments, suitable formulation materials may include, but are not limited to, the following: ·amino acid • Antimicrobial agents such as antibacterial and antifungal drugs • Antioxidant Buffers, buffer systems, and buffering agents used to maintain a composition at or slightly below physiological pH, typically within a pH range of about 5 to about 8 or 9. • Non-aqueous solvents, vegetable oils, and organic esters for injection • Aqueous carriers such as water, alcoholic / aqueous solutions, emulsions or suspensions, such as physiological saline solutions and buffer media. • Biodegradable polymers such as polyester • Volume expander Chelatives • Isotonic agents and absorption retarders • Complexing agent • Filler ·carbohydrates Preferably, a human-derived (low molecular weight) protein, polypeptide, or protein carrier. • Colorants and flavorings • Sulfur-containing reducing agent • Diluent ·emulsifier • Hydrophilic polymer • Salt-forming counterions • Preservatives • Metal complex • Solvents and co-solvents • Sugars and sugar alcohols • Suspension • Surfactants or bluing agents • Stabilizer • Isotonic enhancers • Parenteral delivery media • Intravenous delivery medium.
[0159] It is common knowledge that various components of a pharmaceutical composition can have different effects. For example, amino acids can act as buffers, stabilizers, and / or antioxidants; mannitol can act as a volume extender and / or isotonic enhancer; and sodium chloride can act as a delivery medium and / or isotonic enhancer.
[0160] In the context of the present invention, the pharmaceutical composition is as follows: (a) polypeptides or polypeptide constructs as described herein, (b) at least one type of buffer, (c) at least one type of sugar, and (d) at least one surfactant It may contain [the specified substance], and the pH of the pharmaceutical composition is in the range of 3.5 to 6.
[0161] In the above-described composition, the first domain preferably has an isoelectric point (pI) in the range of 4 to 9.5, the second domain has a pI in the range of 8 to 10, preferably 8.5 to 9.0, and the construct optionally includes a third domain containing two polypeptide monomers, each containing a hinge, a CH2 domain and a CH3 domain, the two polypeptide monomers being fused to each other via a peptide linker.
[0162] In the above-described composition, it is further assumed that at least one buffering agent is present in a concentration range of 5 to 200 mM, more preferably in a concentration range of 10 to 50 mM. It is also assumed that at least one sugar is selected from the group consisting of monosaccharides, disaccharides, cyclic polysaccharides, sugar alcohols, linear branched dextran, or linear unbranched dextran. The disaccharide is also assumed to be selected from the group consisting of sucrose, trehalose, mannitol, sorbitol, and combinations thereof. It is further assumed that the sugar alcohol is sorbitol. It is also assumed that at least one sugar is present in a concentration range of 1 to 15% (m / V), preferably in a concentration range of 9 to 12% (m / V). It is further assumed that the construct is present in a concentration range of 0.1 to 8 mg / ml, preferably 0.2 to 2.5 mg / ml, more preferably 0.25 to 1.0 mg / ml.
[0163] According to one embodiment of the composition described above, at least one surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, Pluronic F68, Triton X-100, polyoxyethylene, PEG 3350, PEG 4000, and combinations thereof. Furthermore, it is assumed that at least one surfactant is present at a concentration in the range of 0.004 to 0.5% (m / V), preferably in the range of 0.001 to 0.01% (m / V). The pH of the composition is assumed to be in the range of 4.0 to 5.0, preferably 4.2. The pharmaceutical composition is also assumed to have an osmolality in the range of 150 to 500 mOsm. Furthermore, it is assumed that the pharmaceutical composition further comprises an excipient selected from the group consisting of one or more polyols and one or more amino acids. In the context of the present invention, it is assumed that one or more excipients are present in a concentration range of 0.1 to 15% (w / V).
[0164] The present invention also provides a pharmaceutical composition comprising (a) a construct described herein in a concentration range of preferably 0.1 to 8 mg / ml, preferably 0.2 to 2.5 mg / ml, more preferably 0.25 to 1.0 mg / ml, (b) 10 mM glutamate or acetate, (c) 9% (m / V) sucrose or 6% (m / V) sucrose and 6% (m / V) hydroxypropyl-β-cyclodextrin, and (d) 0.01% (m / V) polysorbate 80, wherein the pH of the liquid pharmaceutical composition is 4.2.
[0165] The compositions of the present invention may, in addition to the constructs of the present invention as defined herein, contain further biologically active agents depending on the intended use of the composition. Such agents may include drugs that act on the gastrointestinal system, drugs that act as cell proliferation inhibitors, drugs that prevent hyperuricemia, drugs that suppress the immune response, drugs that modulate inflammatory responses, drugs that act on the circulatory system, and / or cytokines known in the art. Furthermore, the polypeptide constructs of the present invention may also be used in combination therapy, i.e., in combination with other anticancer drugs.
[0166] In this regard, the pharmaceutical composition of the present invention (including a construct comprising a CD3-binding domain and at least one further binding domain that binds to a cell surface target antigen, preferably a tumor antigen on the surface of a target cell, as described in more detail herein) is envisioned to further comprise an activator, preferably an antibody or construct, that binds to a protein of the immune checkpoint pathway (such as PD-1 or CTLA-4) or a co-stimulatory immune checkpoint receptor (such as 4-1BB). The present invention also refers to a combination of a polypeptide construct according to the present invention (including a construct comprising a CD3-binding domain and at least one further binding domain that binds to a cell surface target antigen, preferably a tumor antigen on the surface of a target cell, as described in more detail herein) and an activator, preferably an antibody or polypeptide construct, that binds to a protein of the immune checkpoint pathway (such as PD-1 or CTLA-4) or a co-stimulatory immune checkpoint receptor (such as 4-1BB). Due to the properties of at least two components of the combination, i.e., their pharmaceutically active properties, the combination may also be referred to as a therapeutic combination. In some embodiments, the combination may be in the form of a pharmaceutical composition or a kit. According to one embodiment, a pharmaceutical composition or combination comprises a construct of the present invention and an antibody or construct that binds to PD-1. Anti-PD-1 binding proteins useful for this purpose are described in detail, for example, in PCT / US2019 / 013205, which is incorporated herein by reference.
[0167] In certain embodiments, the optimal pharmaceutical composition is determined, for example, by the intended route of administration, the form of delivery, and the desired dosage. See, for example, Remington's Pharmaceutical Sciences cited above. In certain embodiments, such a composition may affect the physical state, stability, in vivo release rate, and in vivo clearance rate of the construct of the present invention. In certain embodiments, the main vehicle or carrier in the pharmaceutical composition may actually be either aqueous or non-aqueous. For example, a suitable vehicle or carrier may be water for injection or a saline solution supplemented with other materials sometimes found in parenteral administration compositions. In certain embodiments, a composition containing the construct of the present invention may be prepared for storage in the form of a lyophilized cake or aqueous solution by mixing selected components having a desired degree of purity with an optional formulation agent (Remington's Pharmaceutical Sciences, cited above). Furthermore, in certain embodiments, the construct of the present invention may be formulated as a lyophilized product using appropriate excipients.
[0168] When parenteral administration is intended, the therapeutic composition for use in the present invention may be provided in the form of a pyrogen-free, parenterally acceptable aqueous solution containing the desired construct of the present invention in a pharmaceutically acceptable vehicle. A vehicle particularly suitable for parenteral injection is sterile distilled water, in which the construct of the present invention is formulated as a well-preserved sterile isotonic solution. In certain embodiments, this preparation may involve formulating the desired molecule with a drug or activator that can result in a controlled or sustained release of the formulation that can be delivered by depot injection, or that can promote the duration of effectiveness in circulation. In certain embodiments, the desired construct may be introduced using an implantable drug delivery device.
[0169] Further pharmaceutical compositions, including formulations containing the constructs of the present invention in sustained delivery or controlled delivery formulations, will be apparent to those skilled in the art. Techniques for formulating various sustained delivery or controlled delivery means are known to those skilled in the art. The constructs can also be encapsulated in microcapsules prepared in colloidal drug delivery systems or in macroemulsions, for example, by coacervate technology or interfacial polymerization. Such techniques are disclosed in the aforementioned Remington's Pharmaceutical Sciences.
[0170] Pharmaceutical compositions used for in vivo administration are typically supplied as sterile preparations. Sterilization can be achieved by filtration through a sterile filtration membrane. When the composition is freeze-dried, sterilization using this method may be performed before or after freeze-drying and reconstitution. Parenteral compositions can be stored in freeze-dried form or in solution. Parenteral compositions are generally placed in containers with a sterile access port, such as intravenous solution bags or vials with a stopper that can be punctured with a subcutaneous needle.
[0171] Another aspect of the present invention includes a self-buffering formulation comprising the construct of the present invention, which can be used as a pharmaceutical composition, as described in International Publication No. 2006 / 138181. Various publications are available regarding protein stabilization and useful formulation materials and methods therein, including Arawaka T. et al., Pharm Res. 1991 Mar;8(3):285-91, Kendrick et al. “Physical stabilization of proteins in aqueous solution” in: Rational Design of Stable Protein Formulations: Theory and Practice, Carpenter and Manning, eds. Pharmaceutical Biotechnology. 13:61-84 (2002), and Randolph and Jones, Pharm Biotechnol. 2002;13:159-75, in particular the sections relating to excipients and processes for self-buffering protein formulations, especially protein pharmaceuticals and processes for use in veterinary and / or human medicine.
[0172] Salts may be used, according to certain embodiments of the present invention, for example, to adjust the ionic strength and / or isotonicity of a composition or formulation, and / or to improve the solubility and / or physical stability of a construct or other component of a composition according to the present invention. Ions can stabilize native proteins by binding to charged residues on the surface of proteins and shielding the charged and polar groups of proteins, thereby reducing the intensity of their electrostatic, attractive, and repulsive interactions. Ions can also stabilize denatured proteins, particularly by binding to denatured peptide bonds (--CONH) of proteins. Furthermore, ionic interactions with charged and polar groups in proteins can also reduce intermolecular electrostatic interactions, thereby preventing or reducing protein aggregation and insolubilization.
[0173] Ionic species exhibit remarkably different effects on proteins. Several categorical rankings of ions and their effects on proteins have been developed for use in formulating pharmaceutical compositions according to the present invention. One example is the Hofmeister series, which ranks ionic and polar nonionic solutes according to their effect on the conformational stability of proteins in solution. Stabilizing solutes are referred to as "cosmotropic." Destabilizing solutes are referred to as "chaotropic." Cosmotropes are generally used at high concentrations to precipitate proteins from solution ("salting out"). Chaotropes are generally used to denature and / or solubilize proteins ("salting out"). The relative effectiveness of ions for "salting out" and "salting out" defines the position of ions in the Hofmeister series.
[0174] Free amino acids can be used in formulations or compositions containing constructs of the present invention according to various embodiments of the present invention as bulking agents, stabilizers, and antioxidants, as well as for other standard uses. Certain amino acids can be used to stabilize proteins in formulations, while others are useful during lyophilization to ensure the correct cake structure and properties of the active ingredients. Some amino acids may be useful in inhibiting protein aggregation in both liquid and lyophilized formulations, while others are useful as antioxidants.
[0175] Polyols are cosmotropic and useful as stabilizers in both liquid and lyophilized formulations to protect proteins from physical and chemical degradation processes. Polyols are also useful for adjusting the tonicity of formulations, protecting them from freeze-thaw stress during transport, or for bulk preparation during manufacturing. Polyols can also function as cryoprotective substances in the context of this invention.
[0176] Certain embodiments of formulations or compositions containing the constructs of the present invention may include surfactants. Proteins readily adsorb to surfaces, are easily denatured, and consequently tend to aggregate at gas-liquid, solid-liquid, and liquid-liquid interfaces. These harmful interactions generally increase or decrease in magnitude inversely proportional to protein concentration and are typically aggravated by physical disturbances, such as those occurring during product delivery and handling. Surfactants are routinely used to prevent, minimize, or reduce surface adsorption. Surfactants are also commonly used to control the conformational stability of proteins. In this regard, the use of surfactants is protein-specific, as one particular surfactant will typically stabilize some proteins and destabilize others.
[0177] Certain embodiments of formulations or compositions containing the constructs of the present invention may include one or more antioxidants. Harmful oxidation of proteins in pharmaceutical formulations can be prevented to some extent by maintaining appropriate levels of ambient oxygen and ambient temperature, and by avoiding exposure to light. Antioxidant excipients can also be used to prevent oxidative degradation of proteins. Antioxidants for use in therapeutic protein formulations according to the present invention are expected to be water-soluble and to maintain their activity throughout the shelf life of the product (composition containing the constructs). Antioxidants can also damage proteins, and for this reason, they should be selected in such a way that, in particular, the possibility of antioxidants damaging the constructs or other proteins in the formulation is eliminated or sufficiently reduced.
[0178] Certain embodiments of formulations or compositions containing the constructs of the present invention may include one or more preservatives. Preservatives are necessary, for example, when developing multi-dose parenteral formulations that involve dispensing from the same container more than once. Their primary function is to inhibit microbial growth over the shelf life or shelf life of the formulation, thereby ensuring the sterility of the product. While preservatives have a long history of use with small molecule parenteral substances, developing protein formulations containing preservatives can be challenging. Preservatives very often cause instability (aggregation) in proteins, which is a major reason why their use in multi-dose protein formulations is limited. To date, most protein drugs have been formulated for single use only. However, the possibility of multi-dose formulations offers the added advantages of patient convenience and high marketability. Human growth hormone (hGH), for example, is a good example of this, as the development of a preservative formulation led to the commercialization of a more convenient multi-dose injectable pen. Several aspects should be considered during the formulation and development of preservative formulations. The effective preservative concentration in a drug product must be optimized. This requires testing a given preservative in a dosage form for a concentration range that provides antimicrobial efficacy without compromising protein stability.
[0179] As expected, developing liquid formulations containing preservatives is more challenging than developing lyophilized formulations. Freeze-dried products can be lyophilized without preservatives and reconstituted with a preservative-containing diluent at the time of use. This reduces the time the preservative is in contact with the construct, significantly minimizing the associated stability risks. In liquid formulations, the efficacy and stability of the preservative should be maintained throughout the entire shelf life of the product. It is important to note that the efficacy of the preservative must be demonstrated in the final formulation containing the active drug and all excipient components. After formulation, pharmaceutical compositions may be stored in sterile vials as liquids, suspensions, gels, emulsions, solids, crystalline preparations, or as dehydrated or lyophilized powders. Such formulations may be stored either in a ready-to-use form or in a form that is reconstituted (e.g., lyophilized) before administration.
[0180] The bioactivity of the pharmaceutical compositions as defined herein can be determined, for example, by in vitro cytotoxicity assays, as described in the following examples, in International Publication No. 99 / 54440, or by Schlereth et al. (Cancer Immunol.Immunother.20(2005),1-12). As used herein, “efficacy” or “in vivo efficacy” refers to the response to therapy with the pharmaceutical compositions of the present invention, for example, using standardized NCI response criteria. The success or in vivo efficacy of therapy using the pharmaceutical compositions of the present invention refers to the efficacy of the composition in relation to its intended purpose, i.e., the composition’s ability to cause its desired effect, i.e., a drastic reduction in diseased cells, such as tumor cells. In vivo efficacy can be monitored by established standard methods for each disease entity, including but not limited to leukocyte count, differentiation, fluorescence cell analysis isolation, and bone marrow aspiration. Furthermore, various disease-specific clinical chemistry parameters and other established standard methods may be used. Furthermore, computed tomography, X-ray, magnetic resonance imaging, positron emission tomography scanning, lymph node biopsy / histological methods, and other established standard methods can be used.
[0181] Another major challenge in the development of drugs, such as the pharmaceutical compositions of the present invention, is the predictable regulation of pharmacokinetic properties. To this end, it is possible to establish a pharmacokinetic profile of a candidate drug, i.e., a profile of pharmacokinetic parameters that influence the ability of a particular drug to treat a given condition. Pharmacokinetic parameters of a drug that influence the ability of a drug to treat certain diseases include, but are not limited to, half-life, volume of distribution, first-pass metabolism in the liver, and degree of serum binding. The efficacy of a given drug may be influenced by each of the above parameters.
[0182] "Half-life" is the time it takes for a substance to decrease to half of its initial value. In medical science, it refers to the half-life of a substance or drug in the human body. In medical context, half-life can refer to the time it takes for a substance / drug to lose half of its activity, e.g., pharmacological, physiological, or radioactive activity. Half-life can also represent the time it takes for the concentration of a drug or substance (e.g., the construct of this invention) in plasma / serum to reach half of its steady-state value ("serum half-life"). Typically, the elimination or removal of an administered substance / drug refers to the cleansing of the body through biological processes such as metabolism and excretion, including the functions of the kidneys and liver. "First-pass metabolism" is the drug metabolism phenomenon in which the concentration of a drug is reduced before it reaches circulation. This is the proportion of the drug lost during the absorption process. Therefore, "hepatic first-pass metabolism" means the tendency for a drug to be metabolized when it first comes into contact with the liver, i.e., while it is first passing through the liver. "Volume of distribution" (VD) refers to the extent to which a drug is distributed to body tissues rather than plasma, with a higher VD indicating a greater amount distributed in tissues. Drug retention can occur in various compartments of the body, including intracellular and extracellular spaces, tissues, and organs. "Serum binding degree" refers to the tendency for a drug to interact with and bind to serum proteins such as albumin, which can lead to a decrease or loss of the drug's biological activity.
[0183] Pharmacokinetic parameters also include the bioavailability, delay time (T lag), Tmax, absorption rate, and / or Cmax of a given amount of drug administered. "Bioavailability" refers to the percentage of the administered dose of the drug / substance that reaches the systemic circulation (blood compartments). When a drug is administered intravenously, its bioavailability is considered to be 100%. However, when a drug is administered via other routes (e.g., orally), its bioavailability generally decreases. "Delay time" refers to the time delay between the administration of a drug and its detectability and measurability in the blood or plasma. Cmax is the maximum plasma concentration a drug achieves after its administration (and before the administration of a second dose). Tmax is the time to reach Cmax. The time it takes to reach the blood or tissue concentration of the drug necessary for its biological effect is influenced by all of these parameters. For pharmacokinetic parameters of constructs exhibiting interspecies specificity that can be determined in preclinical animal studies in primates other than chimpanzees, as outlined above, please refer, for example, to Schlereth et al. (cited above).
[0184] One embodiment provides a construct of the present invention (or a construct manufactured by the method of the present invention) for use as a pharmaceutical, particularly for use in the prevention, treatment, or improvement (preferably treatment) of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors. Another embodiment provides the use of a construct of the present invention (or a construct manufactured by the method of the present invention) in the manufacture of a pharmaceutical for the prevention, treatment, or improvement of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors. It is also conceivable to provide a method for the prevention, treatment, or improvement of diseases, preferably neoplastic diseases, more preferably neoplasms, cancer, or tumors, comprising the step of administering a construct of the present invention (or a construct manufactured according to the method of the present invention) to a subject in need thereof. The terms “subject in need,” “patient,” or “subject in need of treatment” include persons who are already afflicted and persons for whom the disease should be prevented. The terms also include human and other mammalian subjects receiving either prophylactic or therapeutic treatment.
[0185] The polypeptides / polypeptide constructs of the present invention and the formulations / pharmaceutical compositions described herein are useful in treating, improving and / or preventing the medical conditions described herein in patients who require them. The term “treatment” includes both therapeutic treatment and prophylactic or preventative measures. Treatment includes the application or administration of polypeptides / polypeptide constructs / pharmaceutical compositions to the body, isolated tissues, or cells of a patient or subject having a disease / disorder, a symptom of such disease / disorder, or a predisposition to such disease / disorder, for the purpose of curing, healing, alleviating, reducing, altering, correcting, mitigating, improving, or influencing the disease, the symptoms of the disease, or a predisposition to the disease. The term “improvement” as used herein refers to any improvement in the patient’s condition by administering the polypeptide constructs according to the present invention to such patient or subject who requires them. Such improvement may be a delay or cessation of disease progression and / or a decrease in the severity of disease symptoms, an increase in the frequency or duration of disease-free periods, or prevention of functional impairment or disability due to the disease. As used herein, the term “prevention” means avoidance of the occurrence or recurrence of any disease specified herein by administration of the construct according to the present invention to any subject in need thereof.
[0186] The term “disease” refers to any condition that would benefit from treatment with the constructs or pharmaceutical compositions described herein. This includes chronic and acute disorders or diseases, including pathological conditions that make mammals susceptible to the disease in question. Diseases are preferably neoplastic diseases, more preferably neoplasms, cancers, or tumors. Diseases, neoplasms, cancers, or tumors are preferably positive for tumor antigens, preferably those defined herein above, i.e., characterized by the expression or overexpression of tumor antigens, preferably those defined herein above. Overexpression of tumor antigens means an increase of at least 10%, particularly at least 25%, at least 50%, at least 100%, at least 250%, at least 500%, at least 750%, at least 1000%, or more. The expression is preferably found only in diseased tissue, but the expression in corresponding healthy tissue is undetectable or not significantly detectable. According to the present invention, diseases associated with cells expressing tumor antigens, preferably those defined herein above, include cancerous diseases. Furthermore, according to the present invention, cancerous diseases are preferably those in which cancer cells express tumor antigens. In accordance with the present invention, diseases, preferably neoplastic diseases, more preferably neoplasms, tumors, or cancers, are preferably characterized by the presence of BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive cells.In other words, neoplastic diseases, more preferably neoplasms, tumors, or cancers are preferably associated with the presence of BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive cells. Therefore, neoplastic diseases, more preferably neoplasms, tumors, or cancers may be referred to as BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive neoplasms, tumors, or cancers. It is understood herein that each of such tumor antigen-positive neoplasms, tumors, or cancers may be prevented, treated, or improved using polypeptides or polypeptide constructs according to the present invention that include a binding domain to the tumor antigen expressed by the cells in which the neoplasm, tumor, or cancer is associated.Neoplasms, tumors, or cancers that are BCMA-positive, CD123-positive, CD19-positive, CD20-positive, CD22-positive, CD33-positive, CD70-positive, CDH19-positive, CDH3-positive, CLL1-positive, CS1-positive, CLDN6-positive, CLDN18.2-positive, DLL3-positive, EGFRvIII-positive, FLT3-positive, MAGEB2-positive, MART1-positive, MSLN-positive, MUC17-positive, PSMA-positive, or STEAP1-positive are BCMA-positive (for BCMA-positive neoplasms, tumors, or cancers), CD12-positive 3 (for CD123-positive neoplasms, tumors, or cancers), CD19 (for CD19-positive neoplasms, tumors, or cancers), CD20 (for CD20-positive neoplasms, tumors, or cancers), CD22 (for CD22-positive neoplasms, tumors, or cancers), CD33 (for CD33-positive neoplasms, tumors, or cancers), CD70 (for CD70-positive neoplasms, tumors, or cancers), CDH19 (for CDH19-positive neoplasms, tumors, or cancers), CDH3 (for CDH3-positive neoplasms, tumors, or cancers), CLL1 ( Polypeptides or polypeptide constructs according to the present invention, each containing a binding domain to CLL1-positive neoplasms, tumors, or cancers, CS1 (for CS1-positive neoplasms, tumors, or cancers), CLDN6 (for CLDN6-positive neoplasms, tumors, or cancers), CLDN18.2 (for CLDN18.2-positive neoplasms, tumors, or cancers), DLL3 (for DLL3-positive neoplasms, tumors, or cancers), EGFRvIII (for EGFRvIII-positive neoplasms, tumors, or cancers), FLT3 (for FLT3-positive neoplasms, tumors, or cancers), MAGEB2 (for MAGEB2-positive neoplasms, tumors, or cancers), MART1 (for MART1-positive neoplasms, tumors, or cancers), MSLN (for MSLN-positive neoplasms, tumors, or cancers), MUC17 (for MUC17-positive neoplasms, tumors, or cancers), PSMA (for PSMA-positive neoplasms, tumors, or cancers), and STEAP1 (for STEAP1-positive neoplasms, tumors, or cancers), can be used to prevent, treat, or improve these conditions.
[0187] A "neoplasm" is an abnormal growth of tissue that usually forms a mass, though not always. When it forms a mass, it is usually called a "tumor." Neoplasms or tumors can be benign, potentially malignant (precancerous), or malignant (cancerous). Malignant neoplasms / tumors are commonly called cancer. They usually invade and destroy surrounding tissues and may form metastases, that is, they spread to other parts, tissues, or organs of the body. A "primary tumor" is a tumor that grows in an anatomical site where the tumor's progression began and progressed to form a cancerous mass. Most cancers originate in their primary site but then progress and metastasize or spread to other parts of the body (e.g., tissues and organs). These further tumors are "secondary tumors." Most cancers continue to be named after their primary site even after they have spread to other parts of the body.
[0188] Lymphoma and leukemia are lymphoid neoplasms. For the purposes of this invention, they are also encompassed by the terms “tumor” and “cancer.” For the purposes of this invention, the terms “neoplasm,” “tumor,” and “cancer” may be used interchangeably and include both primary tumors / cancers and secondary tumors / cancers (or “metastases”), as well as mass-forming neoplasms (tumors) and lymphoid neoplasms (such as lymphoma and leukemia), and minimal residual disease (MRD).
[0189] The term “minimum residual disease” (MRD) refers to evidence of the presence of a small number of residual cancer cells remaining in a patient after cancer treatment, for example, when the patient is in remission (no symptoms or signs of the disease). Standard tests used to assess or detect cancer are not sensitive enough to detect MRD, so typically very small numbers of residual cancer cells cannot be detected by routine means. Recently, highly sensitive molecular biological tests for MRD, such as flow cytometry, PCR, and next-generation sequencing, have become available. These tests can measure the minimum level of cancer cells in a tissue sample, sometimes as low as one cancer cell in a million normal cells. In the context of this invention, the terms “prevention,” “treatment,” or “improvement” of cancer are assumed to also encompass “prevention, treatment, or improvement of MRD,” regardless of whether MRD has been detected.
[0190] The constructs of the present invention will generally be designed to suit specific routes and methods of administration, specific dosages and frequencies of administration, and specific treatments for specific diseases, particularly in terms of bioavailability and persistence. The materials of the composition will preferably be formulated at concentrations acceptable at the administration site. Thus, formulations and compositions can be designed in accordance with the present invention to suit delivery by any suitable route of administration. In the context of the present invention, routes of administration include, but are not limited to, local, enteral, and parenteral routes.
[0191] If the pharmaceutical composition is lyophilized, the lyophilized material is first reconstituted with a suitable liquid before administration. The lyophilized material can be reconstituted with, for example, bacteriostatic water for injection (BWFI), physiological saline solution, phosphate-buffered saline solution (PBS), or the same formulation in which the protein was present before lyophilization. The pharmaceutical compositions and antibody constructs of the present invention are particularly useful for parenteral administration, such as intravenous delivery, such as injection or infusion. The pharmaceutical compositions may be administered using medical devices. Examples of medical devices for administering pharmaceutical compositions are described in U.S. Patent Nos. 4,475,196; 4,439,196; 4,447,224; 4,447,233; 4,486,194; 4,487,603; 4,596,556; 4,790,824; 4,941,880; 5,064,413; 5,312,335; 5,312,335; 5,383,851; and 5,399,163.
[0192] The compositions of the present invention can be administered to subjects at appropriate doses, which can be determined, for example, by dose-escalation studies. As described above, the constructs of the present invention exhibiting heterospecificity as described herein can also be advantageously used in preclinical studies in non-chimpanzee primates. The administration plan will be determined by the attending physician based on clinical factors. As is well known in the medical field, the drug dose for any one patient depends on many factors, including the patient's size, body surface area, age, the specific compound to be administered, sex, time and route of administration, overall health status, and other drugs administered concurrently.
[0193] The “effective dose” is the amount of therapeutic agent sufficient to achieve, or at least partially achieve, the desired effect. The “therapeutic effective dose” is the amount sufficient to cure, or at least partially suppress, the disease and its complications, signs, and symptoms in a patient suffering from the disease. The effective dose or amount for this use will depend on the disease being treated (target disease), the construct being delivered, the circumstances and objectives of the treatment, the severity of the disease, previous therapy, the patient’s medical history and response to the drug, the route of administration, the patient’s size (weight, body surface) and / or condition (age and overall health), and the patient’s overall immune system status. To obtain the optimal therapeutic effect, the appropriate dose may be adjusted at the discretion of the attending physician.
[0194] A therapeutically effective dose of the construct of the present invention preferably results in a reduction in the severity of disease symptoms, an increase in the frequency or duration of disease-free periods, or prevention of disease-related functional impairment or disability. In the treatment of tumor antigen-expressing tumors, a therapeutically effective dose of the construct of the present invention containing a binding domain to the tumor antigen preferably inhibits tumor cell growth by at least about 20%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to untreated patients. The ability of the compound to inhibit tumor growth can also be evaluated in animal models, which serve as predictive indicators of efficacy in human tumors.
[0195] In further embodiments, the present invention provides a kit comprising a construct of the present invention, a construct prepared by a method of the present invention, a polynucleotide of the present invention, a vector of the present invention, and / or a host cell of the present invention. In the context of the present invention, the term “kit” means two or more components packaged together in a container, recipient, or otherwise, one of which corresponds to a construct of the present invention, a pharmaceutical composition, a polynucleotide, a vector, or a host cell. Thus, a kit can be described as a set of products and / or tools sufficient to achieve a particular purpose that can be sold individually.
[0196] Further components of the kit of the present invention are envisioned to be agents, preferably antibodies or constructs, that bind to proteins of the immune checkpoint pathway (such as PD-1 or CTLA-4) or co-stimulatory immune checkpoint receptors (such as 4-1BB). Such agents are described in more detail above herein. According to one embodiment, the kit comprises the construct of the present invention and an antibody or construct that binds to PD-1. Anti-PD-1 binding proteins useful for this purpose are described in detail, for example, in PCT / US2019 / 013205. In certain embodiments, the kit allows for simultaneous and / or sequential administration of the components.
[0197] The kit may include one or more containers of any suitable shape, size, and material (preferably waterproof, e.g., plastic or glass) containing a drug dose of the construct or pharmaceutical composition of the present invention suitable for administration (see above). The kit may further include instructions for use (e.g., in the form of a booklet or instruction manual), means for administering the construct or pharmaceutical composition of the present invention, means for reconstituting the construct of the present invention, and / or means for diluting the construct of the present invention, such as a syringe, pump, injector or similar device.
[0198] The present invention also provides kits for single-dose units. The kits of the present invention may include a first container containing a dried / freeze-dried construct or pharmaceutical composition and a second container containing an aqueous formulation. In certain embodiments of the present invention, kits are provided containing pre-filled syringes with single and multiple chambers.
[0199] Whenever the term “construction” is used herein, such term refers to a polypeptide / polypeptide construct used in the present invention or a counterpart thereof, as shown.
[0200] Where used herein, the singular forms “a,” “an,” and “the” include plural references unless otherwise specifically indicated by the context. For example, a reference to “reagent” includes one or more such various reagents, and a reference to “method” includes references to equivalent steps and methods known to those skilled in the art, which may be modified for or substituted for the methods described herein.
[0201] Unless otherwise specified, the term “at least” preceding a set of elements shall be understood to refer to all elements within that set. Those skilled in the art will be able to recognize or confirm, through mere routine experimentation, many equivalents to certain embodiments of the invention described herein. Such equivalents shall be incorporated herein.
[0202] As used herein, the term "and / or" includes the meanings of "and," "or," and "all or any other combination of the elements connected by that term."
[0203] As used herein, the terms “about” or “approximately” mean within ±20%, preferably ±15%, more preferably ±10%, and most preferably ±5% of a given value or range. This also includes specific values; for example, “about 50” includes the value “50”.
[0204] Throughout this specification and the claims, unless specifically required by context, variations such as “comprise,” “comprises,” and “contains” shall be understood to imply that they include the integer or process or group of integers or processes described, but not exclude any other integer or process or group of integers or processes. Where used herein, the term “comprising” may be replaced by the terms “containing” or “including,” or where used herein, by the term “having.”
[0205] As used herein, “consisting of” excludes any element, process, or component not specified in the elements of the claims. As used herein, “essentially consisting of” does not exclude materials or processes that do not substantially affect the basic and novel features of the claims.
[0206] In each example herein, “including,” “essentially consisting of,” and “consisting of” may be replaced with any of the other two terms.
[0207] The above description and the following examples provide illustrative arrangements, but the present invention is not limited to, and may differ from, the specific methodologies, techniques, protocols, materials, reagents, substances, etc., described herein. The terms used herein are for the purpose of describing specific embodiments only. The terms used herein are not intended to limit the scope of the present invention and are defined solely by the claims. Aspects of the present invention are provided in the independent claims. Some optional features of the present invention are provided in the dependent claims.
[0208] All publications and patents cited throughout this specification (including all patents, patent applications, scientific publications, manufacturer specifications, instructions, etc.), whether above or below, are incorporated by reference in their entirety by this specification. Nothing in this specification shall be construed as an acknowledgment that the present invention has no prior rights to such disclosure by prior art. This specification supersedes any material incorporated by reference to the extent that such material is inconsistent with or contradicts this specification.
[0209] A better understanding of the present invention and its advantages can be obtained from the following examples, which are provided for illustrative purposes only. The examples are not to be construed as limiting the scope of the invention in any way. [Brief explanation of the drawing]
[0210] [Figure 1] G4S vs. G4R linkers in CD33 BiTE® molecular variants, analyzed by SDS-PAGE without stress testing. [Figure 2] This is a PSMA BiTE® variant analyzed by SDS-PAGE without stress testing. [Figure 3] This is a target 2 TDCC assay. [Figure 4] This is a target 1 TDCC assay. [Figure 5] This is a direct comparison between the PSMA BiTE® molecule and an optimized variant of the BiTE molecule. [Figure 6] This is a schematic diagram showing the clipping site detected by the BiTE molecule Z5S and the stabilization introduced. [Examples]
[0211] Example 1: Materials and Method Generation and expression of the BiTE molecule Individual DNA fragments from the open reading frame were sequenced for gene synthesis and subcloned into a mammalian expression vector using standard cloning methods. The expression vector contained an IgG-derived signal peptide for secretory expression into cell culture supernatant. Sequence-confirmed plasmid clones were transferred into CHO cells, and the cell culture supernatant from the stable cell pool was collected after 7 days. The cell culture supernatant was stored at -80°C until the protein was purified.
[0212] BiTE purification chromatography analysis Protein purification was performed by affinity chromatography using Protein A (Cytiva, Mab Select SuRe column), followed by size exclusion chromatography (HiLoad® 16 / 600 Superdex® 200pg GE Healthcare). Peaks were pooled using the OD280nm signal (blue), and the mass matrix was analyzed by SDS-PAGE. Protein monomer peaks were mixed in 10 mM citrate, 75 mM lysine, and 4% trehalose, and divided into fixed volumes for storage at -80°C.
[0213] SDS-PAGE analysis The samples were denatured at 95°C for 5 minutes and then applied to non-reductive (-DTT) or reductive (+DTT) SDS-PAGE. The gels were then stained / destained with instant blue to visualize the protein bands.
[0214] In vitro FACS coupled analysis Purified BiTE® antibody constructs were subjected to flow cytometry to determine binding to target antigen-transferred CHO cells, human CD3-positive T cell lines (HPB-ALL), or human PBMCs from healthy volunteers. BiTE molecules were stained with PE anti-human IgG (1:200). The assay was performed with 100 / 10 / 1 / 0.1 nM BiTE® molecules at 4°C for 30 minutes. Staining was based on cells stained only with secondary anti-human Fc-specific PE-binding polyclonal AB.
[0215] FACS-based cytotoxic assay using unstimulated human PBMCs Isolation of effector cells Human peripheral blood mononuclear cells (PBMCs) were prepared from concentrated lymphocyte preparations (buffycoat), a byproduct of blood banks that collect blood for transfusion, by Ficol density gradient centrifugation. Buffycoat was supplied by peripheral blood banks, and PBMCs were prepared the day after blood collection. After Ficol density centrifugation and thorough washing with Dulbecco's PBS (Gibco), residual erythrocytes were removed from the PBMCs via incubation with erythrocyte lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 100 μM EDTA). Residual lymphocytes mainly consisted of B lymphocytes, T lymphocytes, NK cells, and monocytes. The PBMCs were maintained under culture in RPMI medium (Gibco) containing 10% FCS (Gibco) at 37°C / 5% CO2.
[0216] Isolation of pan-T cells Human T cells were isolated from PBMCs using the Miltenyi Biotec Human Pan-T Cell Isolation Kit (130-096-535) according to the protocol provided with the kit. Next, T cells were isolated using an LS column (Milteny Biotec, #130-042-401). The T cells were cultured in RPMI 1640 (Biochrom AG, #FG1215) supplemented with 10% FBS (Bio West, #S1810), 1× non-essential amino acids (Biochrom AG, #K0293), 10 mM Hepes buffer (Biochrom AG, #L1613), 1 mM sodium pyruvate (Biochrom AG, #L0473), and 100 U / mL penicillin / streptomycin (Biochrom AG, #A2213) in an incubator at 37°C until required.
[0217] Target cell labeling For the analysis of cell lysis in flow cytometry assays, target-transplanted CHO cells were labeled as target cells using the fluorescent membrane dye DiOC18 (DiO) (Thermo Fisher, #V22886) to distinguish them from effector cells. Briefly, cells were harvested, washed once with PBS, and adjusted to 10e6 cells / mL in PBS containing 2% (v / v) FBS and the membrane dye DiO (5 μL / 10e6 cells). After incubation at 37°C for 3 minutes, the cells were washed twice with complete RPMI medium to adjust the cell count to 1.25 × 10e5 cells / mL. Cell activity was measured using Nucleocounter NC-250 (Chemometec) and Solution 18 dye containing acridine orange and DAPI (Chemometec).
[0218] Flow cytometry-based analysis This assay was designed to quantify the lysis of CHO cells translocated with cynomolgus monkey (cyno) or human targets in the presence of serial dilutions of bispecific antibody constructs. Equivolutes of DiO-labeled target cells and effector cells (i.e., PBMCs without CD14+ cells) were mixed to obtain an E:T cell ratio of 10:1. 160 μl of this suspension was transferred to each well of a 96-well plate. 40 μl serial dilutions of the corresponding target × CD3 bispecific antibody construct and negative control bispecificity (CD3-based bispecific antibody construct recognizing an unrelated target antigen) or RPMI complete medium as an additional negative control were added. A bispecific antibody-mediated cytotoxic reaction was allowed to proceed for 48 hours in a humidified incubator at 7% CO2. The cells were then transferred to a new 96-well plate, and loss of target cell membrane integrity was monitored by adding propidium iodide (PI) at a final concentration of 1 μg / mL. PIs are typically membrane-impermeable dyes that are eliminated from living cells, whereas dead cells take them up and become identifiable through fluorescence emission.
[0219] Samples were measured by flow cytometry using an iQue Plus (Intellicyt, now Sartorius) instrument and analyzed using Forecyt software (Intellicyt). Target cells were identified as DiO-positive cells. PI-negative target cells were classified as viable target cells. The percentage of cytotoxicity was calculated using the following formula.
number
[0220] Using GraphPad Prism 7.04 software (Graph Pad Software, San Diego), the percentage of cytotoxicity was plotted against the corresponding bispecific antibody construct concentration. Dose-response curves were analyzed using four parametric logistic regression models for evaluating sigmoid dose-response curves with a fixed Hill slope, and EC50 values were calculated.
[0221] Stress test of the sample Thermal decomposition was induced by incubating the sample in formulation buffer at 40°C for 4 weeks. The sample in the formulation was adjusted to pH 7.2 using phosphate buffer solution (PBS), and physiological pH decomposition (pH jump) was induced by subsequent incubation at 37°C for 4 weeks.
[0222] Solution preparation A denaturation buffer (6M guanidine HCl, 200mM Tris, 20mM methionine, pH 8.3) was prepared by adding 20 mL of 1 M (hydroxymethyl)aminomethane hydrochloride (Tris), pH 8.3 (Teknova, St. Louis, MO, P / N T1083) to 87.5 mL of 8M guanidine HCl (Pierce, Rockford, IL, P / N 24115), followed by the addition of 299 mg of L-methionine (JTBaker, P / N 2085-05). The pH of this solution was adjusted to pH 8.3 using either 1N hydrochloric acid (HCl) (Ricca, Arlington, TX, P / N R3700100-120A) or 1N sodium hydroxide (NaOH) (Merck, Kenilworth, NJ, P / N 1.09137.100). The volume was adjusted to 100 mL using HPLC-grade water. The reducing solution (500 mM DTT) was prepared by dissolving 7.7 mg of pre-weighed dithiothreitol (DTT) (Pierce, Rockford, IL, P / N 20291) in 100 μL of denaturation buffer. Alkylation solution (500 mM NaIAA) was prepared by dissolving 15–65 mg of sodium iodide acetate (NaIAA) (Sigma, St. Louis, MO, P / N I-9148) in a sufficient volume of denaturing buffer to produce 500 mM NaIAA. Digestion buffer (50 mM tris, 20 mM methionine, pH 7.8) was prepared by dissolving 299 mg of L-methionine in 10 mL of 1 M tris, pH 7.8, and adding 100 mL of HPLC-grade water. The pH of this solution was adjusted to 7.8 using either 1N hydrochloride (HCl) (Ricca, Arlington, TX, P / N R3700100-120A) or 1N sodium hydroxide (NaOH) (Merck, Kenilworth, NJ, P / N 1.09137.100), and the volume was adjusted to 100 mL using HPLC-grade water.Enzyme solutions (1 mg / mL trypsin, 1 mg / mL neutrophil elastase) were prepared by adding 100 μg of digestion buffer to 100 μg of trypsin (Roche, Basel, Switzerland, P / N 03708969001) or 100 μg of neutrophil elastase (Elastin Products Company, Owensville, MO, P / N SE563). Digestion quenching solutions (8 M guanidine HCl, 250 mM guanidine acetate, pH 4.7) were prepared by dissolving 76.4 g of guanidine HCl (Sigma, St. Louis, MO, P / N 50933) and 1.0 g of sodium acetate (Sigma, P / N 32319) in 95 mL of HPLC-grade water. Next, 716 μL of glacial acetic acid (Sigma, St. Louis, MO, P / N 320099) was added, and the pH was adjusted to pH 4.7 using either HCl or NaOH. The volume was then adjusted to 100 mL using HPLC-grade water.
[0223] MWCO spin filter-assisted continuous digestion 200 μL of denaturation buffer was added to a 30 kDa molecular weight cutoff rotating apparatus consisting of a membrane unit placed in a centrifuge tube for filtrate collection (Millipore, Billerica, MA, P / N MRCF0R030 or Pall, Port Washington, NY, P / N OD030C34). This apparatus was rotated at 14,000 × g for 10 minutes using an Eppendorf 5430 centrifuge. The filtrate was discarded. 100 μg of the sample in the formulation buffer was added to the filter apparatus and rotated at 14,000 × g for 10 minutes. The filtrate was discarded. For each sample, 3 μL of reducing solution was added to 37 μL of denaturation buffer, and 40 μL of this solution was added to the filter apparatus. The samples were denatured and reduced by incubation in a 37°C water bath for 30 minutes. For each sample, 7 μL of alkylation solution was added to 33 μL of denaturation buffer, and 40 μL of this solution was added to the filter device. The sample was alkylated by incubation at room temperature in the dark for 20 minutes. For each sample, 4 μL of denaturation solution was added to 36 μL of denaturation buffer, and 40 μL of this solution was added to the filter device to quench the alkylation. Next, the sample was rotated at 14,000 × g for 15 minutes, and the filtrate was discarded. 200 μL of digestion buffer was added to the sample, and the filter device was rotated at 14,000 × g for 15 minutes, the filtrate was discarded, and this was repeated two more times to remove the denaturant, reducing agent, and alkylating agent. For each sample, 5 μL of trypsin solution was added to 35 μL of digestion buffer, and 40 μL of this solution was added to the filter device (enzyme:substrate ratio of 1:20). The sample was incubated in a 37°C water bath for 60 minutes. The filter was transferred to a new collection tube (collection tube 2). The first collection tube (collection tube 1) was removed. The filter was centrifuged at 14,000 × g for 10 minutes. The filtrate containing the trypsin peptide was retained in collection tube 2. 20 μL of digestion buffer was added to the filter, and the filter (inside collection tube 2) was rotated at 14,000 × g for 10 minutes, retaining the filtrate in collection tube 2. This was repeated one more time. The filter was returned to collection tube 1, and collection tube 2 was removed.For each sample, 5 μL of neutrophil elastase solution was added to 35 μL of digestion buffer, and 40 μL of this solution was added to a filter (here, collection tube 1, enzyme:substrate ratio of 1:20, based on the starting material). The sample was incubated in a 37°C water bath for 30 minutes. The filter was transferred to collection tube 2. Collection tube 1 was discarded. The filter was centrifuged at 14,000 × g for 10 minutes. The filtrate containing the peptide resulting from neutrophil elastase digestion was retained in collection tube 2 (along with the trypsin peptide from the previous step). 20 μL of digestion buffer was added to the filter, and the filter (in collection tube 2) was rotated at 14,000 × g for 10 minutes, the filtrate was retained in collection tube 2, and this was repeated once more. Digestion was quenched by adding 160 μL of digestion quenching buffer to collection tube 2.
[0224] UPLC conditions For all samples, mobile phase A consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid in acetonitrile. Peptides were separated using a BEH C18 1.7 μm, 2.1 × 150 mm UPLC column (Waters, Milford, MA, P / N 186003556). UPLC separation was performed using one of the following systems: Thermo Scientific U-3000 system (Waltham, MA), Waters Acquity H-Class system (Milford, MA), and / or Agilent 1290 system (Santa Clara, CA), utilizing the gradient outlined in Table 1. Approximately 3–4 μg of sample was loaded onto the column based on the starting material.
[0225] MS conditions Peptides resulting from digestion were analyzed using Thermo Scientific Q Exactive (Waltham, MA), Thermo Scientific Q Exactive Plus (Waltham, MA), or Thermo Scientific Q Exactive BioPharma (Waltham, MA). Due to the use of multiple instruments, data acquisition parameters varied slightly depending on the instrument. Instruments were operated in a data-dependent manner (top 4-8) over a scanning range of 200–2,000 m / z. The AGC target was set to 1E6 for MS1 scans and 5E5 for MSMS scans. MS1 scans were acquired at either a resolution of 35,000 or 140,000, while MS2 scans were acquired at a resolution of 17,500. An isolation window of 2–4 m / z was identified for MSMS scans. Unused charge states and charge states greater than 8 were excluded from MSMS. Dynamic exclusion was set to 10 seconds. Lock mass at m / z 391.28430 is now possible.
[0226] Data Analysis For peptide identification, MS data were searched using MassAnalyzer (multiple versions of MassAnalyzer were used as data were collected over several months). Carboxymethylation was identified as a static modification. Experimentally, cleavage was identified as either nonspecific or at the C-terminus of the amino acid KRVITAL. For the full search, the signal-to-noise ratio was set to 20, a mass precision of 15 ppm was specified, and the confidence level was set to 0.95. For sequence coverage mapping, the minimum peak area was set to 1% of the base peak, the relative peak area threshold was set to 17%, the minimum confidence level was set to 0.95, and the maximum peptide mass was set to 15,000. For quantification, MS data were processed with Skyline. Skyline workbooks were created using peptides identified in the MassAnalyzer search results.
[0227] [Table 2]
[0228] Example 2: Results SDS-PAGE analysis The purified monomers of the generated BiTE molecules were subjected to SDS-PAGE analysis under non-reductive and / or reductive conditions. With the exception of BiTE molecules (W7V, W8I), all BiTE molecules showed a single band at the expected molecular weight under both conditions. For the BiTE molecules, W7V and W8I, containing the G4R linker repeat, showed additional bands at lower molecular weights, suggesting low molecular weight (LMW) fragments without thermal stress testing.
[0229] Cytotoxic activity All BiTE molecules analyzed showed cytotoxic activity against CHO cells transplanted with the target antigen. The activity was comparable to either the reference standard BiTE molecule (Target 2, Figure 3) or the standard BiTE molecule containing a less affine target binder than the parent (R5C / P2K, Target 1, Figure 4).
[0230] Thermal stress test BiTE molecules were subjected to thermal stress at 40°C for 4 weeks, and subsequently, the increase in %LMW was analyzed compared to the untreated control sample as described.
[0231] Anti-CD3 scFv Substitution of the reference material anti-CD3 scFv with a G4Q linker repeat in BiTE molecules (F8I vs. F1D, Table 1) reduced LMW by 13.3%. Substitution of the reference material anti-CD3 scFv and the reference material single-chain Fc domain with the corresponding stabilizing domain reduced LMW by 40.9% in the G4Q linker configuration (M5J vs. Q8I, Table 1).
[0232] Linker BiTE molecules containing a G4Q linker repeat instead of a G4S linker repeat showed a 35.8% reduction in LMW ratio compared to BiTE molecules containing standard anti-CD3 scFv, manipulated anti-CD3 scFv cis-clamp, and standard scFc domains (11D vs. F8I, Table 1).
[0233] Without manipulated anti-CD3 scFv cis-clamp, BiTE molecules containing the G4Q linker repeat showed a 32.3% lower LMW than BiTE molecules containing the G4S linker (Z5S vs. Q6S, Table 1).
[0234] BiTE molecules containing a standard anti-CD3 scFv without the manipulated anti-CD3 scFv cis-clamp showed a 43.3% reduction in LMW under the G4Q linker repeat compared to the G4S linker repeat (J1X vs. X7D, Table 1).
[0235] scFc domain Standard material vs. stabilized single-stranded Fc domain, standard material CD3 binder, and manipulated anti-CD3 scFv cis-clamp for BiTE molecules containing the G4Q linker repeat showed a 3.2% reduction in LMW (F8I vs. M5J, Table 1).
[0236] When combined with a stabilized CD3 binder and a modified anti-CD3 scFv cis-clamp, modified scFc reduced the LMW ratio to 34.0% (F1D vs. Q8I).
[0237] The G4Q linker repeat combined with the manipulated anti-CD3 scFv standard material anti-CD3 scFv without cis-clamp showed approximately 37.5% lower LMW compared to the stabilized scFc containing the BiTE molecule (Q6S vs. X7D, Table 1). Similarly, the stabilized scFc domain in the BiTE molecule containing the standard material G4S linker repeat, the manipulated anti-CD3 scFv standard material without cis-clamp, showed approximately 26.2% lower LMW than the standard material scFc domain (Z5S vs. J1X, Table 1).
[0238] [Table 3]
[0239] Anti-CD3 scFv operated sys-clamp The introduction of an engineered cis-clamp in anti-CD3 scFv resulted in a 49.3% increase in LMW in the BiTE molecule containing standard anti-CD3 scFv, standard G4S linker repeat, and standard scFc domain, compared to the non-CD3 cis-clamped BiTE molecule counterpart.
[0240] BiTE molecules containing stabilized anti-CD3 scFv, G4Q linker repeat, and standard single-stranded Fc domain showed only a 2.1% increase in LMW compared to the same BiTE molecule without the manipulated cis-clamp, compared to BiTE variants with the manipulated cis-clamp.
[0241] While the BiTE molecule contained stabilized anti-CD3 scFv and G4Q linkers, the modified single-stranded Fc domain showed a 2.6% increase in LMW compared to the BiTE molecule containing CD3-operated cis-clamp.
[0242] Notably, the LMW percentage was negligible for BiTE molecules with manipulated CD3 cis-clamp. However, BiTE molecules containing a stabilizing domain showed a lower LMW percentage compared to the reference molecule, regardless of anti-CD3 scFv cis-clamp (approximately 15.5% LMW vs. 29% without CD3 scFv cis-clamp, or 15.9% vs. 43.3% with CD3 scFv cis-clamp, respectively).
[0243] combination For target-binding molecules, the BiTE molecule S5Z showed the lowest LMW percentage compared to its reference molecule 11S (15.5% vs. 29%, Figure 5). In detail, the 46.6% reduction in total LMW is explained by the reduction of clipping of the anti-CD3 scFv linker, target scFv linker, and scFc domain.
[0244] For the target 2-binding BiTE molecule, X7D showed a total of 9.2% LMW compared to 22.1% LMW of the reference molecule, and thus, stabilization by replacing the G4S linker repeat with G4Q and the wild-type scFc domain with the stabilized scFc domain reduced the LMW to 58.2%.
[0245]
Table 4
[0246]
Table 5
[0247] Conclusion These observations indicate that the stabilization of a single domain or linker (e.g., anti-CD3 scFv, linker, or scFc) itself contributes to the reduction of the LMW% after heat stress. Furthermore, the combination of the G4Q linker, stabilized anti-CD3 scFv, and stabilized BiTE molecule showed an additive effect on the total % LMW (Figure 5, Table 2).
[0248] In the tested BiTE molecules containing the wild-type anti-CD3 scFv, wild-type linker, and wild-type scFc domain, the CD3 cis-clamp engineered as a single modification showed elevated % LMW levels (43.3% vs. 29.0%) in the wild-type BiTE molecule. However, in the context of the stabilized domains, the engineered CD3 cis-clamp showed lower elevated LMW% levels compared to its non-cis-clamp counterpart (2.1% or 2.6%). Notably, the total level of % LMW after heat stress was reduced in the stabilized BiTE molecule containing the CD3 cis-clamp compared to the standard control molecule 11D and compared to the standard BiTE molecule without the anti-CD3 scFv cis-clamp (11S).
[0249] Other motifs showing clipping after heat stress and relief In the anti-target scFv of the BiTE molecule, the inventors identified a cleavage site at the N-terminus of the VL domain starting with the amino acid sequence: DI. Here, the inventors introduce a single amino acid change (e.g., D→E mutation) to reduce this cleavage site.
[0250] Similarly, in the BiTE construct containing the VL-linker-VH order in one of the scFv subunits, the SSS motif (VSS) constructed by the terminus of VH and the SG4X linker showed high cleavage that was addressed by the depletion of one serine in the linker sequence (SG4×→G4X) to generate the SS motif, i.e., (VSSGGGGX).
[0251] Sequence
[0252] [Table 6]
[0253] [Table 7]
[0254] [Table 8]
[0255] [Table 9]
[0256] [Table 10]
[0257] [Table 11]
[0258] [Table 12]
[0259] Table 13
[0260] Table 14
[0261] Table 15
[0262] Table 16
[0263] Table 17
[0264] Table 18
[0265] Table 19
[0266] Table 20
[0267] Table 21
[0268] Table 22
[0269] Table 23
[0270] Table 24
[0271] Table 25
[0272] Table 26
[0273] Table 27
[0274] Table 28
[0275] Table 29
[0276] Table 30
[0277] Table 31
[0278] Table 32
[0279] Table 33
[0280] Table 34
[0281] Table 35
[0282] Table 36
[0283] Table 37
[0284] Table 38
[0285] Table 39
[0286] Table 40
[0287] Table 41
[0288] Table 42
[0289] Table 43
[0290] Table 44
[0291] Table 45
[0292] Table 46
[0293] Table 47
[0294] Table 48
[0295] Table 49
Claims
1. 1. A polypeptide or polypeptide construct comprising a first target antigen binding domain, said first target antigen binding domain comprising VH and VL variable regions linked by a peptide linker, said peptide linker comprising or consisting of S(G4X)n or (G4X)n, wherein X is Q and n is an integer selected from the integers 1 to 20.
2. 2. A polypeptide or polypeptide construct according to claim 1, wherein n is 1, 2, 3, 4, 5 or 6, preferably 3.
3. 3. A polypeptide or polypeptide construct as claimed in claim 1 or 2, comprising at least one further binding domain which binds to a target antigen.
4. 4. The polypeptide or polypeptide construct of claim 3, wherein the at least one further target antigen binding domain comprises the same components as the first target antigen binding domain, preferably each target antigen binding domain binds to one target antigen.
5. 5. The polypeptide or polypeptide construct of claim 3 or 4, wherein the polypeptide or polypeptide construct comprises binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL), preferably wherein the polypeptide or polypeptide construct comprises binding domain 1 (VH / VL-peptide linker-VH / VL)-linker-binding domain 2 (VH / VL-peptide linker-VH / VL)-binding domain 3 (VH / VL-peptide linker-VH / VL), and / or wherein the C-terminal binding domain binds to CD3 and the remaining N-terminal binding domain binds to a cell surface antigen.
6. 6. The polypeptide or polypeptide construct of claim 5, wherein the linker linking the binding domains comprises or consists of S(G4X)n or (G4X)n, where X is selected from the group consisting of Q, T, N, C, G, A, V, I, L and M, and n is an integer selected from the integers 1 to 20, preferably wherein the linker is S(G4X)n, n is 1 and X is Q.
7. 7. The polypeptide or polypeptide construct according to any one of claims 1 to 6, comprising a half-life prolonging domain, preferably said half-life prolonging domain (HLE domain) comprises two polypeptide monomers, each monomer comprising a hinge, a CH2 domain and a CH3 domain, or consists of two polypeptide monomers, each monomer comprising a hinge, a CH2 domain and a CH3 domain, said two polypeptide monomers being fused to each other via a peptide linker comprising, in amino to carboxyl order: hinge-CH2-CH3-peptide linker-hinge-CH2-CH3.
8. A polynucleotide encoding a polypeptide or polypeptide construct according to any one of claims 1 to 7.
9. A vector comprising the polynucleotide of claim 8.
10. A host cell transformed or transfected with a polynucleotide according to claim 8 or a vector according to claim 9.
11. A process for the production of a polypeptide or polypeptide construct according to any one of claims 1 to 7, comprising culturing a host cell according to claim 10 under conditions allowing expression of the polypeptide or polypeptide construct according to any one of claims 1 to 7, and recovering the produced polypeptide or polypeptide construct from the culture.
12. A pharmaceutical composition comprising a polypeptide or polypeptide construct according to any one of claims 1 to 7 or produced by the process according to claim 11.
13. A kit comprising a polypeptide or polypeptide construct according to any one of claims 1 to 7 or produced by the process according to claim 11, a polynucleotide according to claim 8, a vector according to claim 9, and / or a host cell according to claim 10.
